Raras
Buscar doenças, sintomas, genes...
Síndrome epiléptico
ORPHA:166463PCDT · SUSDOENÇA RARA

Uma síndrome que se caracteriza por um conjunto de sintomas e sinais, e/ou por alterações no eletroencefalograma (EEG), que mostram atividade epiléptica. Frequentemente, está associada a outros problemas de saúde, como dificuldades de raciocínio e aprendizado, deficiência intelectual, atrasos no desenvolvimento de movimentos (tanto os amplos, como andar, quanto os mais finos, como escrever), dificuldades de fala e linguagem, e pode afetar outras funções do corpo. Suas causas podem ser específicas — como problemas na estrutura do cérebro, causas genéticas, metabólicas (ligadas ao funcionamento químico do corpo), imunológicas (relacionadas ao sistema de defesa) ou infecciosas — ou sua origem pode ser desconhecida.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Uma síndrome que se caracteriza por um conjunto de sintomas e sinais, e/ou por alterações no eletroencefalograma (EEG), que mostram atividade epiléptica. Frequentemente, está associada a outros problemas de saúde, como dificuldades de raciocínio e aprendizado, deficiência intelectual, atrasos no desenvolvimento de movimentos (tanto os amplos, como andar, quanto os mais finos, como escrever), dificuldades de fala e linguagem, e pode afetar outras funções do corpo. Suas causas podem ser específicas — como problemas na estrutura do cérebro, causas genéticas, metabólicas (ligadas ao funcionamento químico do corpo), imunológicas (relacionadas ao sistema de defesa) ou infecciosas — ou sua origem pode ser desconhecida.

Pesquisas ativas
9 ensaios
316 total registrados no ClinicalTrials.gov
Publicações científicas
1.775 artigos
Último publicado: 2026 Apr 14
Medicamentos
4 registrados
LAMOTRIGINE, RUFINAMIDE, CANNABIDIOL

Tem tratamento?

4 medicamentos registrados
Ver detalhes, fases e interações →
LAMOTRIGINERUFINAMIDECANNABIDIOLTOPIRAMATE
🏥
SUS: Cobertura mínimaScore: 30%
PCDT disponível
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
176 sintomas
😀
Face
33 sintomas
👁️
Olhos
30 sintomas
🦴
Ossos e articulações
30 sintomas
💪
Músculos
23 sintomas
📏
Crescimento
11 sintomas

+ 251 sintomas em outras categorias

Características mais comuns

Sucção pobre
Atraso no desenvolvimento motor fino
Coordenação olho-mão pobre
Fala hipernasal
Atrofia óptica de Leber
Sinusite
613sintomas
Sem dados (613)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 613 características clínicas mais associadas, ordenadas por frequência.

Sucção pobrePoor suck
Atraso no desenvolvimento motor finoDelayed fine motor development
Coordenação olho-mão pobrePoor hand-eye coordination
Fala hipernasalHypernasal speech
Atrofia óptica de LeberLeber optic atrophy

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico1.775PubMed
Últimos 10 anos200publicações
Pico2025105 papers
Linha do tempo
2026Hoje · 2026🧪 1992Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

79 genes identificados com associação a esta condição.

EPM2ALaforin, isoform 9Disease-causing germline mutation(s) inTolerante
LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (2)
Glycogen synthesisMyoclonic epilepsy of Lafora
EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
21.7 TPM
Cólon sigmoide
17.6 TPM
Esôfago - Muscular
16.6 TPM
Esôfago - Junção
14.9 TPM
Brain Spinal cord cervical c-1
13.9 TPM
OUTRAS DOENÇAS (2)
myoclonic epilepsy of Lafora 1Lafora disease
HGNC:3413UniProt:B3EWF7
CDK19Cyclin-dependent kinase 19Candidate gene tested inAltamente restrito
LOCALIZAÇÃO

CytoplasmCytoplasm, perinuclear regionNucleus

VIAS BIOLÓGICAS (3)
RSV-host interactionsTranscriptional regulation of white adipocyte differentiationPPARA activates gene expression
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 87

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE87 inheritance is autosomal dominant.

OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 87undetermined early-onset epileptic encephalopathy
HGNC:19338UniProt:Q9BWU1
GABRA2Gamma-aminobutyric acid receptor subunit alpha-2Candidate gene tested inAltamente restrito
FUNÇÃO

Alpha subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (PubMed:10449790, PubMed:29961870, PubMed:31032849). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interfaces (By similarity). When activated by GABA, GABAARs selectively allow the flow

LOCALIZAÇÃO

Postsynaptic cell membraneCell membraneCytoplasmic vesicle membraneCell projection, dendrite

VIAS BIOLÓGICAS (1)
GABA receptor activation
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 78

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE78 is an autosomal dominant form characterized by onset of refractory seizures in the first days or months of life. Clinical features include severe developmental delay, hypotonia, microcephaly, cortical visual impairment and profound intellectual disability. Some patients manifest a less severe phenotype characterized by pharmacoresponsive epilepsy, autism spectrum disorder and moderate intellectual disability.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Frontal Cortex BA9
11.9 TPM
Brain Nucleus accumbens basal ganglia
10.7 TPM
Brain Caudate basal ganglia
10.7 TPM
Córtex cerebral
10.6 TPM
Brain Anterior cingulate cortex BA24
10.5 TPM
OUTRAS DOENÇAS (3)
developmental and epileptic encephalopathy, 78undetermined early-onset epileptic encephalopathyalcohol dependence
HGNC:4076UniProt:P47869
AARS1Alanine--tRNA ligase, cytoplasmicCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the attachment of alanine to tRNA(Ala) in a two-step reaction: alanine is first activated by ATP to form Ala-AMP and then transferred to the acceptor end of tRNA(Ala) (PubMed:27622773, PubMed:27911835, PubMed:28493438, PubMed:33909043). Also edits incorrectly charged tRNA(Ala) via its editing domain (PubMed:27622773, PubMed:27911835, PubMed:28493438, PubMed:29273753). In presence of high levels of lactate, also acts as a protein lactyltransferase that mediates lactylation of lysine res

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Cytosolic tRNA aminoacylation
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2N

An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

OUTRAS DOENÇAS (6)
trichothiodystrophy 8, nonphotosensitiveleukoencephalopathy, hereditary diffuse, with spheroids 2developmental and epileptic encephalopathy, 29Charcot-Marie-Tooth disease axonal type 2N
HGNC:20UniProt:P49588
GRIN2DGlutamate receptor ionotropic, NMDA 2DCandidate gene tested inAltamente restrito
FUNÇÃO

Component of N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with high calcium permeability and voltage-dependent block by Mg(2+) (PubMed:26875626, PubMed:27616483, PubMed:28126851, PubMed:9489750). Participates in synaptic plasticity for learning and memory formation (By similarity). Channel activation requires binding of the neurotransmitter L-glutamate to the GluN2 subunit, glycine or D-serine binding to the GluN1 subunit, plus me

LOCALIZAÇÃO

Cell membranePostsynaptic cell membrane

VIAS BIOLÓGICAS (8)
RAF/MAP kinase cascadeRas activation upon Ca2+ influx through NMDA receptorUnblocking of NMDA receptors, glutamate binding and activationLong-term potentiationNegative regulation of NMDA receptor-mediated neuronal transmission
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 46

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fibroblastos
6.8 TPM
Hipotálamo
6.1 TPM
Córtex cerebral
4.2 TPM
Brain Anterior cingulate cortex BA24
4.1 TPM
Brain Frontal Cortex BA9
3.6 TPM
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 46undetermined early-onset epileptic encephalopathy
HGNC:4588UniProt:O15399
GABRA5Gamma-aminobutyric acid receptor subunit alpha-5Candidate gene tested inRestrito
FUNÇÃO

Alpha subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (PubMed:14993607, PubMed:29961870, PubMed:30140029, PubMed:31056671). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) (PubMed:30140029). When activated by GABA, GABAARs selec

LOCALIZAÇÃO

Postsynaptic cell membraneCell membrane

VIAS BIOLÓGICAS (1)
GABA receptor activation
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 79

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE79 is an autosomal dominant form characterized by onset of refractory seizures in the first months of life. Brain imaging may show hypomyelination, cerebral atrophy and thinning of the corpus callosum.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Nucleus accumbens basal ganglia
91.3 TPM
Brain Anterior cingulate cortex BA24
37.9 TPM
Brain Frontal Cortex BA9
35.2 TPM
Hipocampo
29.4 TPM
Córtex cerebral
26.2 TPM
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 79undetermined early-onset epileptic encephalopathy
HGNC:4079UniProt:P31644
SLC2A1Solute carrier family 2, facilitated glucose transporter member 1Candidate gene tested inAltamente restrito
FUNÇÃO

Facilitative glucose transporter, which is responsible for constitutive or basal glucose uptake (PubMed:10227690, PubMed:10954735, PubMed:18245775, PubMed:19449892, PubMed:25982116, PubMed:27078104, PubMed:32860739). Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses (PubMed:18245775, PubMed:19449892). Most important energy carrier of the brain: present at the blood-brain barrier and assures the energy-independent, facilitative trans

LOCALIZAÇÃO

Cell membraneMelanosomePhotoreceptor inner segment

VIAS BIOLÓGICAS (3)
Vitamin C (ascorbate) metabolismCellular hexose transportRegulation of insulin secretion
MECANISMO DE DOENÇA

GLUT1 deficiency syndrome 1

A neurologic disorder showing wide phenotypic variability. The most severe 'classic' phenotype comprises infantile-onset epileptic encephalopathy associated with delayed development, acquired microcephaly, motor incoordination, and spasticity. Onset of seizures, usually characterized by apneic episodes, staring spells, and episodic eye movements, occurs within the first 4 months of life. Other paroxysmal findings include intermittent ataxia, confusion, lethargy, sleep disturbance, and headache. Varying degrees of cognitive impairment can occur, ranging from learning disabilities to severe intellectual disability.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
703.8 TPM
Skin Not Sun Exposed Suprapubic
272.6 TPM
Skin Sun Exposed Lower leg
265.8 TPM
Vagina
176.1 TPM
Esôfago - Mucosa
154.8 TPM
OUTRAS DOENÇAS (8)
childhood onset GLUT1 deficiency syndrome 2hereditary cryohydrocytosis with reduced stomatindystonia 9encephalopathy due to GLUT1 deficiency
HGNC:11005UniProt:P11166
MAPK10Mitogen-activated protein kinase 10Candidate gene tested inRestrito
FUNÇÃO

Serine/threonine-protein kinase involved in various processes such as neuronal proliferation, differentiation, migration and programmed cell death. Extracellular stimuli such as pro-inflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK10/JNK3. In turn, MAPK10/JNK3 phosphorylates a number of transcription f

LOCALIZAÇÃO

CytoplasmMembraneNucleusMitochondrion

VIAS BIOLÓGICAS (3)
Oxidative Stress Induced SenescenceFCERI mediated MAPK activationJNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
EXPRESSÃO TECIDUAL(Ubíquo)
Brain Frontal Cortex BA9
40.5 TPM
Córtex cerebral
29.8 TPM
Brain Anterior cingulate cortex BA24
21.9 TPM
Cérebro - Hemisfério cerebelar
19.8 TPM
Cerebelo
16.9 TPM
OUTRAS DOENÇAS (1)
Lennox-Gastaut syndrome
HGNC:6872UniProt:P53779
FRRS1LDOMON domain-containing protein FRRS1LCandidate gene tested inTolerante
FUNÇÃO

Important modulator of glutamate signaling pathway

LOCALIZAÇÃO

Cell membraneSynapse

MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 37

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE37 is an autosomal recessive, severe form manifesting in the first years of life. Affected individuals show hyperkinetic movement disorder with choreoathetosis, spasticity, rigidity, intellectual disability, absent speech, and impaired volitional movements.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
53.7 TPM
Cerebelo
43.9 TPM
Brain Frontal Cortex BA9
29.1 TPM
Brain Nucleus accumbens basal ganglia
27.6 TPM
Córtex cerebral
22.6 TPM
OUTRAS DOENÇAS (3)
developmental and epileptic encephalopathy, 37developmental and/or epileptic encephalopathy with spike-wave activation in sleepautosomal recessive non-syndromic intellectual disability
HGNC:1362UniProt:Q9P0K9
KCNT1Potassium channel subfamily T member 1Candidate gene tested inTolerante
FUNÇÃO

Sodium-activated K(+) channel (PubMed:37494189). Acts as an important mediator of neuronal membrane excitability (PubMed:37494189). Contributes to the delayed outward currents (By similarity). Regulates neuronal bursting in sensory neurons (By similarity). Contributes to synaptic development and plasticity (By similarity)

LOCALIZAÇÃO

Cell membrane

MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 14

A rare epileptic encephalopathy of infancy that combines pharmacoresistant seizures with developmental delay. This severe neurologic disorder is characterized by onset in the first 6 months of life of refractory focal seizures and arrest of psychomotor development. Ictal EEG shows discharges that arise randomly from various areas of both hemispheres and migrate from one brain region to another.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cerebelo
94.7 TPM
Cérebro - Hemisfério cerebelar
80.1 TPM
Córtex cerebral
44.1 TPM
Brain Frontal Cortex BA9
30.4 TPM
Baço
20.2 TPM
OUTRAS DOENÇAS (4)
developmental and epileptic encephalopathy, 14autosomal dominant nocturnal frontal lobe epilepsy 5malignant migrating partial seizures of infancyautosomal dominant nocturnal frontal lobe epilepsy
HGNC:18865UniProt:Q5JUK3
PLCB11-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1Candidate gene tested inAltamente restrito
FUNÇÃO

Catalyzes the hydrolysis of 1-phosphatidylinositol 4,5-bisphosphate into diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) and mediates intracellular signaling downstream of G protein-coupled receptors (PubMed:9188725). Regulates the function of the endothelial barrier

LOCALIZAÇÃO

Nucleus membraneCytoplasm

VIAS BIOLÓGICAS (8)
Synthesis of IP3 and IP4 in the cytosolPLC beta mediated eventsG alpha (q) signalling eventsG beta:gamma signalling through PLC betaCa2+ pathway
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 12

A form of epilepsy characterized by frequent tonic seizures or spasms beginning in infancy with a specific EEG finding of suppression-burst patterns, characterized by high-voltage bursts alternating with almost flat suppression phases. Patients may progress to West syndrome, which is characterized by tonic spasms with clustering, arrest of psychomotor development, and hypsarrhythmia on EEG.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Frontal Cortex BA9
16.7 TPM
Brain Caudate basal ganglia
10.1 TPM
Cólon sigmoide
8.6 TPM
Brain Putamen basal ganglia
8.1 TPM
Córtex cerebral
8.0 TPM
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 12malignant migrating partial seizures of infancy
HGNC:15917UniProt:Q9NQ66
SLC12A5Solute carrier family 12 member 5Candidate gene tested inAltamente restrito
FUNÇÃO

Mediates electroneutral potassium-chloride cotransport in mature neurons and is required for neuronal Cl(-) homeostasis (PubMed:12106695). As major extruder of intracellular chloride, it establishes the low neuronal Cl(-) levels required for chloride influx after binding of GABA-A and glycine to their receptors, with subsequent hyperpolarization and neuronal inhibition (By similarity). Involved in the regulation of dendritic spine formation and maturation (PubMed:24668262)

LOCALIZAÇÃO

Cell membraneCell projection, dendrite

VIAS BIOLÓGICAS (1)
Cation-coupled Chloride cotransporters
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 34

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE34 is characterized by onset of refractory migrating focal seizures in infancy. Affected children show developmental regression and are severely impaired globally.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
208.8 TPM
Cerebelo
204.3 TPM
Brain Frontal Cortex BA9
97.0 TPM
Córtex cerebral
73.3 TPM
Brain Nucleus accumbens basal ganglia
51.3 TPM
OUTRAS DOENÇAS (3)
developmental and epileptic encephalopathy, 34malignant migrating partial seizures of infancyepilepsy, idiopathic generalized, susceptibility to, 14
HGNC:13818UniProt:Q9H2X9
DMXL2DmX-like protein 2Candidate gene tested inAltamente restrito
FUNÇÃO

May serve as a scaffold protein for MADD and RAB3GA on synaptic vesicles (PubMed:11809763). Plays a role in the brain as a key controller of neuronal and endocrine homeostatic processes (By similarity)

LOCALIZAÇÃO

Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membraneCytoplasmic vesicle, secretory vesicle, neuronal dense core vesicle

MECANISMO DE DOENÇA

Polyendocrine-polyneuropathy syndrome

A progressive endocrine and neurodevelopmental disorder manifesting early in childhood with growth retardation and recurrent episodes of profound asymptomatic hypoglycemia. PEPNS is characterized by central hypothyroidism, hypogonadotropic hypogonadism, incomplete puberty, progressive non-autoimmune insulin-dependent diabetes mellitus, peripheral demyelinating sensorimotor polyneuropathy, and cerebellar and pyramidal signs.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
22.0 TPM
Cerebelo
20.8 TPM
Pituitária
16.6 TPM
Pulmão
14.8 TPM
Testículo
13.9 TPM
OUTRAS DOENÇAS (5)
developmental and epileptic encephalopathy, 81polyendocrine-polyneuropathy syndromehearing loss, autosomal dominant 71early-infantile DEE
HGNC:2938UniProt:Q8TDJ6
GRIN1Glutamate receptor ionotropic, NMDA 1Candidate gene tested inAltamente restrito
FUNÇÃO

Component of N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with high calcium permeability and voltage-dependent block by Mg(2+) (PubMed:21376300, PubMed:26875626, PubMed:26919761, PubMed:28126851, PubMed:28228639, PubMed:36959261, PubMed:7679115, PubMed:7681588, PubMed:7685113). NMDARs participate in synaptic plasticity for learning and memory formation by contributing to the long-term potentiation (LTP) (PubMed:26875626). Channel

LOCALIZAÇÃO

Cell membranePostsynaptic cell membranePostsynaptic density membraneSynaptic cell membrane

VIAS BIOLÓGICAS (9)
RAF/MAP kinase cascadeRas activation upon Ca2+ influx through NMDA receptorUnblocking of NMDA receptors, glutamate binding and activationLong-term potentiationNegative regulation of NMDA receptor-mediated neuronal transmission
MECANISMO DE DOENÇA

Neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal dominant

An autosomal dominant neurodevelopmental disorder characterized by severe intellectual disability and developmental delay, absent speech, muscular hypotonia, dyskinesia, and hyperkinetic movements. Cortical blindness, cerebral atrophy, and seizures are present in some patients.

EXPRESSÃO TECIDUAL(Tecido-específico)
Córtex cerebral
222.8 TPM
Cerebelo
219.9 TPM
Brain Frontal Cortex BA9
191.7 TPM
Cérebro - Hemisfério cerebelar
171.8 TPM
Brain Nucleus accumbens basal ganglia
119.2 TPM
OUTRAS DOENÇAS (7)
neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal dominantneurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal recessivedevelopmental and epileptic encephalopathy 101early-infantile DEE
HGNC:4584UniProt:Q05586
GNAO1Guanine nucleotide-binding protein G(o) subunit alphaCandidate gene tested inDesconhecido
FUNÇÃO

Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signaling cascades (PubMed:29925951, PubMed:33408414). The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state (By similarity). Signaling by an activated GPCR promotes GDP release and GTP binding (By similarity). The alpha subunit has a low GTPase activity that converts bound

LOCALIZAÇÃO

Cell membraneMembrane

VIAS BIOLÓGICAS (1)
Ca2+ pathway
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 17

A severe neurologic disorder characterized by onset of intractable seizures in the first weeks or months of life and usually associated with EEG abnormalities. Affected infants have very poor psychomotor development and may have brain abnormalities, such as cerebral atrophy or thin corpus callosum. Some patients may show involuntary movements.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
92.1 TPM
Cérebro - Hemisfério cerebelar
82.9 TPM
Brain Frontal Cortex BA9
82.9 TPM
Córtex cerebral
79.5 TPM
Brain Caudate basal ganglia
74.3 TPM
OUTRAS DOENÇAS (4)
neurodevelopmental disorder with involuntary movementsdevelopmental and epileptic encephalopathy, 17GNAO1-related developmental delay-seizures-movement disorder spectrumearly-infantile DEE
HGNC:4389UniProt:P09471
SCN1ASodium channel protein type 1 subunit alphaCandidate gene tested inAltamente restrito
FUNÇÃO

Pore-forming subunit of Nav1.1, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes. Navs, also called VGSCs (voltage-gated sodium channels) or VDSCs (voltage-dependent sodium channels), operate by switching between closed and open conformations depending on the voltage difference across the membrane. In the open conformation they allow Na(+) ions to selectively pass through the pore, along their electrochemical gradient.

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Interaction between L1 and AnkyrinsPhase 0 - rapid depolarisation
MECANISMO DE DOENÇA

Generalized epilepsy with febrile seizures plus 2

A rare autosomal dominant, familial condition with incomplete penetrance and large intrafamilial variability. Patients display febrile seizures persisting sometimes beyond the age of 6 years and/or a variety of afebrile seizure types. This disease combines febrile seizures, generalized seizures often precipitated by fever at age 6 years or more, and partial seizures, with a variable degree of severity.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Frontal Cortex BA9
15.1 TPM
Cérebro - Hemisfério cerebelar
10.7 TPM
Cerebelo
9.3 TPM
Córtex cerebral
8.9 TPM
Hipotálamo
6.3 TPM
OUTRAS DOENÇAS (13)
developmental and epileptic encephalopathy, 6Ageneralized epilepsy with febrile seizures plus, type 2developmental and epileptic encephalopathy 6Bfamilial hemiplegic migraine
HGNC:10585UniProt:P35498
CELF2CUGBP Elav-like family member 2Candidate gene tested inAltamente restrito
FUNÇÃO

RNA-binding protein implicated in the regulation of several post-transcriptional events. Involved in pre-mRNA alternative splicing, mRNA translation and stability. Mediates exon inclusion and/or exclusion in pre-mRNA that are subject to tissue-specific and developmentally regulated alternative splicing. Specifically activates exon 5 inclusion of TNNT2 in embryonic, but not adult, skeletal muscle. Activates TNNT2 exon 5 inclusion by antagonizing the repressive effect of PTB. Acts both as an activ

LOCALIZAÇÃO

NucleusCytoplasm

MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 97

A form of epileptic encephalopathy, a heterogeneous group of early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE97 is an autosomal dominant form.

OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy 97undetermined early-onset epileptic encephalopathy
HGNC:2550UniProt:O95319
CACNA2D1Voltage-dependent calcium channel subunit alpha-2/delta-1Candidate gene tested inAltamente restrito
FUNÇÃO

The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel (PubMed:35293990). Plays an important role in excitation-contraction coupling (By similarity)

LOCALIZAÇÃO

MembraneCell membrane

VIAS BIOLÓGICAS (1)
Presynaptic depolarization and calcium channel opening
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 110

A form of epileptic encephalopathy, a heterogeneous group of early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE110 is an autosomal recessive form characterized by profound global developmental delay and hypotonia apparent in infancy followed by onset of seizures in the first months or years of life.

OUTRAS DOENÇAS (4)
developmental and epileptic encephalopathy 110undetermined early-onset epileptic encephalopathyBrugada syndromeshort QT syndrome
HGNC:1399UniProt:P54289
PACS2Phosphofurin acidic cluster sorting protein 2Candidate gene tested inAltamente restrito
FUNÇÃO

Multifunctional sorting protein that controls the endoplasmic reticulum (ER)-mitochondria communication, including the apposition of mitochondria with the ER and ER homeostasis. In addition, in response to apoptotic inducer, translocates BIB to mitochondria, which initiates a sequence of events including the formation of mitochondrial truncated BID, the release of cytochrome c, the activation of caspase-3 thereby causing cell death. May also be involved in ion channel trafficking, directing acid

LOCALIZAÇÃO

Endoplasmic reticulumMitochondrion

MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 66

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE66 is an autosomal dominant form characterized by onset of seizures in first days or weeks of life.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
188.4 TPM
Cerebelo
113.5 TPM
Cérebro - Hemisfério cerebelar
101.9 TPM
Nervo tibial
89.5 TPM
Substância negra
70.5 TPM
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 66undetermined early-onset epileptic encephalopathy
HGNC:23794UniProt:Q86VP3
FBXO28F-box only protein 28Candidate gene tested inAltamente restrito
FUNÇÃO

Substrate-recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex, promoting ubiquitination and proteasomal degradation of specific target proteins including TOP2A, RAB27A or itself (PubMed:27754753, PubMed:31678254). Regulates topoisomerase IIalpha/TOP2A decatenation activity and plays an important role in maintaining genomic stability (PubMed:27754753). Plays a role in lipid metabolism and inflammation through the ubiquitinated degradation of RAB27A (By simi

LOCALIZAÇÃO

Chromosome, centromere, kinetochoreNucleusChromosome

MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 100

A form of epileptic encephalopathy, a heterogeneous group of early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE100 is an autosomal dominant, severe form characterized by global developmental delay and onset of variable types of seizures in the first months or years of life.

EXPRESSÃO TECIDUAL(Ubíquo)
Skin Sun Exposed Lower leg
30.6 TPM
Skin Not Sun Exposed Suprapubic
26.9 TPM
Fibroblastos
21.6 TPM
Cérebro - Hemisfério cerebelar
20.7 TPM
Artéria tibial
20.0 TPM
INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy 100undetermined early-onset epileptic encephalopathy
HGNC:29046UniProt:Q9NVF7
DNM1Dynamin-1Candidate gene tested inAltamente restrito
FUNÇÃO

Catalyzes the hydrolysis of GTP and utilizes this energy to mediate vesicle scission and participates in many forms of endocytosis, such as clathrin-mediated endocytosis or synaptic vesicle endocytosis as well as rapid endocytosis (RE) (PubMed:15703209, PubMed:20428113, PubMed:29668686, PubMed:8101525, PubMed:8910402, PubMed:9362482). Associates to the membrane, through lipid binding, and self-assembles into rings and stacks of interconnected rings through oligomerization to form a helical polym

LOCALIZAÇÃO

Cell membraneMembrane, clathrin-coated pitCytoplasmic vesiclePresynapseCytoplasmic vesicle, secretory vesicle, chromaffin granule

VIAS BIOLÓGICAS (7)
Gap junction degradationFormation of annular gap junctionsRetrograde neurotrophin signallingRecycling pathway of L1MHC class II antigen presentation
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 31A

An autosomal dominant epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
373.8 TPM
Cérebro - Hemisfério cerebelar
367.4 TPM
Brain Frontal Cortex BA9
260.3 TPM
Córtex cerebral
254.5 TPM
Brain Anterior cingulate cortex BA24
127.4 TPM
OUTRAS DOENÇAS (4)
developmental and epileptic encephalopathy, 31Adevelopmental and epileptic encephalopathy, 31Bundetermined early-onset epileptic encephalopathyLennox-Gastaut syndrome
HGNC:2972UniProt:Q05193
YEATS2YEATS domain-containing protein 2Candidate gene tested inRestrito
FUNÇÃO

Chromatin reader component of the ATAC complex, a complex with histone acetyltransferase activity on histones H3 and H4 (PubMed:18838386, PubMed:19103755, PubMed:27103431). YEATS2 specifically recognizes and binds histone H3 crotonylated at 'Lys-27' (H3K27cr) (PubMed:27103431). Crotonylation marks active promoters and enhancers and confers resistance to transcriptional repressors (PubMed:27103431)

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (2)
HATs acetylate histonesFormation of WDR5-containing histone-modifying complexes
MECANISMO DE DOENÇA

Epilepsy, familial adult myoclonic, 4

A form of familial myoclonic epilepsy, a neurologic disorder characterized by cortical hand tremors, myoclonic jerks and occasional generalized or focal seizures with a non-progressive or very slowly progressive disease course. Usually, myoclonic tremor is the presenting symptom, characterized by tremulous finger movements and myoclonic jerks of the limbs increased by action and posture. In a minority of patients, seizures are the presenting symptom. Some patients exhibit mild cognitive impairment. FAME4 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
39.3 TPM
Linfócitos
37.5 TPM
Cerebelo
36.2 TPM
Fibroblastos
31.4 TPM
Ovário
28.9 TPM
OUTRAS DOENÇAS (2)
epilepsy, familial adult myoclonic, 4benign adult familial myoclonic epilepsy
HGNC:25489UniProt:Q9ULM3
NPRL3GATOR1 complex protein NPRL3Candidate gene tested inRestrito
FUNÇÃO

As a component of the GATOR1 complex functions as an inhibitor of the amino acid-sensing branch of the mTORC1 pathway (PubMed:23723238, PubMed:29590090, PubMed:35338845). In response to amino acid depletion, the GATOR1 complex has GTPase activating protein (GAP) activity and strongly increases GTP hydrolysis by RagA/RRAGA (or RagB/RRAGB) within heterodimeric Rag complexes, thereby turning them into their inactive GDP-bound form, releasing mTORC1 from lysosomal surface and inhibiting mTORC1 signa

LOCALIZAÇÃO

Lysosome membrane

VIAS BIOLÓGICAS (1)
Amino acids regulate mTORC1
EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
54.0 TPM
Testículo
52.7 TPM
Sangue
52.6 TPM
Cerebelo
46.3 TPM
Nervo tibial
45.0 TPM
OUTRAS DOENÇAS (2)
epilepsy, familial focal, with variable foci 3familial focal epilepsy with variable foci
HGNC:14124UniProt:Q12980
ADORA2AAdenosine receptor A2aCandidate gene tested inTolerante
FUNÇÃO

Receptor for adenosine (By similarity). The activity of this receptor is mediated by G proteins which activate adenylyl cyclase (By similarity)

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
G alpha (s) signalling eventsSurfactant metabolismAdenosine P1 receptors
OUTRAS DOENÇAS (1)
acute encephalopathy with biphasic seizures and late reduced diffusion
HGNC:263UniProt:P29274
TRIM8E3 ubiquitin-protein ligase TRIM8Candidate gene tested inAltamente restrito
FUNÇÃO

E3 ubiquitin-protein ligase that participates in multiple biological processes including cell survival, differentiation, apoptosis, and in particular, the innate immune response (PubMed:27981609, PubMed:28747347). Participates in the activation of interferon-gamma signaling by promoting proteasomal degradation of the repressor SOCS1 (PubMed:12163497). Plays a positive role in the TNFalpha and IL-1beta signaling pathways. Mechanistically, induces the 'Lys-63'-linked polyubiquitination of MAP3K7/T

LOCALIZAÇÃO

CytoplasmNucleusNucleus, nuclear body

VIAS BIOLÓGICAS (1)
Interferon gamma signaling
MECANISMO DE DOENÇA

Focal segmental glomerulosclerosis and neurodevelopmental syndrome

An autosomal dominant disorder characterized by global developmental delay associated with variable features of focal segmental glomerulosclerosis, a renal pathology defined by the presence of segmental sclerosis in glomeruli and resulting in proteinuria, reduced glomerular filtration rate and progressive decline in renal function. Some patients have transient proteinuria and others require renal transplant. Neurodevelopmental features are also variable, with some patients having only mildly impaired intellectual development, and others having a severe developmental disorder associated with early-onset refractory seizures or epileptic encephalopathy. Additional features, including feeding difficulties, poor overall growth, and non-specific dysmorphic facial features, are commonly observed.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
178.8 TPM
Cervix Endocervix
158.3 TPM
Tireoide
154.4 TPM
Tecido adiposo
150.5 TPM
Aorta
149.7 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (2)
focal segmental glomerulosclerosis and neurodevelopmental syndromeearly-infantile DEE
HGNC:15579UniProt:Q9BZR9
EFHC1EF-hand domain-containing protein 1Candidate gene tested inTolerante
FUNÇÃO

Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in cilia axoneme, which is required for motile cilia beating (PubMed:36191189). Microtubule-associated protein which regulates cell division and neuronal migration during cortical development (PubMed:19734894, PubMed:28370826). Necessary for radial and tangential cell migration during brain development, possibly acting as a regulator of cell morphology and process formation during migration (PubMed:22926142)

LOCALIZAÇÃO

Cytoplasm, cytoskeleton, cilium axonemeCytoplasm, cytoskeleton, flagellum axonemeCytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm, cytoskeleton, spindleCytoplasm, cytoskeleton, spindle pole

MECANISMO DE DOENÇA

Juvenile myoclonic epilepsy 1

A subtype of idiopathic generalized epilepsy. Patients have afebrile seizures only, with onset in adolescence (rather than in childhood) and myoclonic jerks which usually occur after awakening and are triggered by sleep deprivation and fatigue.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
17.6 TPM
Tireoide
13.0 TPM
Testículo
12.7 TPM
Cervix Endocervix
11.6 TPM
Fallopian Tube
10.2 TPM
OUTRAS DOENÇAS (3)
juvenile absence epilepsyjuvenile myoclonic epilepsyepilepsy, juvenile absence, susceptibility to, 1
HGNC:16406UniProt:Q5JVL4
YWHAG14-3-3 protein gammaCandidate gene tested inAltamente restrito
FUNÇÃO

Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways (PubMed:15696159, PubMed:16511572, PubMed:36732624). Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif (PubMed:15696159, PubMed:16511572, PubMed:36732624). Binding generally results in the modulation of the activity of the binding partner (PubMed:16511572). Promotes inactivation of WDR24 component of the GATOR2 complex by bindi

LOCALIZAÇÃO

Cytoplasm, cytosolMitochondrion matrix

VIAS BIOLÓGICAS (10)
Recruitment of mitotic centrosome proteins and complexesLoss of proteins required for interphase microtubule organization from the centrosomeLoss of Nlp from mitotic centrosomesRegulation of PLK1 Activity at G2/M TransitionAURKA Activation by TPX2
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 56

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE56 is an autosomal dominant condition.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Frontal Cortex BA9
554.5 TPM
Cérebro - Hemisfério cerebelar
317.8 TPM
Brain Anterior cingulate cortex BA24
299.5 TPM
Córtex cerebral
261.1 TPM
Hipotálamo
238.6 TPM
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 56undetermined early-onset epileptic encephalopathy
HGNC:12852UniProt:P61981
SZT2KICSTOR complex protein SZT2Candidate gene tested inRestrito
FUNÇÃO

As part of the KICSTOR complex functions in the amino acid-sensing branch of the TORC1 signaling pathway. Recruits, in an amino acid-independent manner, the GATOR1 complex to the lysosomal membranes and allows its interaction with GATOR2 and the RAG GTPases. Functions upstream of the RAG GTPases and is required to negatively regulate mTORC1 signaling in absence of amino acids. In absence of the KICSTOR complex mTORC1 is constitutively localized to the lysosome and activated. The KICSTOR complex

LOCALIZAÇÃO

Lysosome membranePeroxisome

VIAS BIOLÓGICAS (1)
Amino acids regulate mTORC1
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 18

A severe autosomal recessive neurologic disorder characterized by lack of psychomotor development apparent from birth, dysmorphic facial features, early onset of refractory seizures, and thick corpus callosum and persistent cavum septum pellucidum on brain imaging.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
25.3 TPM
Testículo
24.8 TPM
Ovário
22.8 TPM
Pituitária
22.4 TPM
Cerebelo
22.3 TPM
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 18undetermined early-onset epileptic encephalopathy
HGNC:29040UniProt:Q5T011
KCNC2Voltage-gated potassium channel KCNC2Candidate gene tested inTolerante
FUNÇÃO

Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain. Contributes to the regulation of the fast action potential repolarization and in sustained high-frequency firing in neurons of the central nervous system. Homotetramer channels mediate delayed-rectifier voltage-dependent potassium currents that activate rapidly at high-threshold voltages and inactivate slowly. Forms tetrameric channels through which potassium ions pass

LOCALIZAÇÃO

Cell membraneMembranePerikaryonCell projection, axonCell projection, dendritePostsynaptic cell membranePresynaptic cell membraneSynapse, synaptosomeSynapseApical cell membraneBasolateral cell membrane

VIAS BIOLÓGICAS (2)
Glucagon-like Peptide-1 (GLP1) regulates insulin secretionVoltage gated Potassium channels
EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Frontal Cortex BA9
37.0 TPM
Brain Anterior cingulate cortex BA24
22.2 TPM
Córtex cerebral
22.1 TPM
Pituitária
9.7 TPM
Hipotálamo
9.1 TPM
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy 103undetermined early-onset epileptic encephalopathy
HGNC:6234UniProt:Q96PR1
ATP6V1AV-type proton ATPase catalytic subunit ACandidate gene tested inAltamente restrito
FUNÇÃO

Catalytic subunit of the V1 complex of vacuolar(H+)-ATPase (V-ATPase), a multisubunit enzyme composed of a peripheral complex (V1) that hydrolyzes ATP and a membrane integral complex (V0) that translocates protons (PubMed:8463241). V-ATPase is responsible for acidifying and maintaining the pH of intracellular compartments and in some cell types, is targeted to the plasma membrane, where it is responsible for acidifying the extracellular environment (PubMed:32001091). In aerobic conditions, invol

LOCALIZAÇÃO

CytoplasmCytoplasm, cytosolCytoplasmic vesicle, secretory vesicleCytoplasmic vesicle, clathrin-coated vesicle membraneLysosome

VIAS BIOLÓGICAS (6)
Insulin receptor recyclingTransferrin endocytosis and recyclingIon channel transportROS and RNS production in phagocytesAmino acids regulate mTORC1
MECANISMO DE DOENÇA

Cutis laxa, autosomal recessive, 2D

A form of cutis laxa, a disorder characterized by an excessive congenital skin wrinkling, a large fontanelle with delayed closure, a typical facial appearance with downslanting palpebral fissures, and a general connective tissue weakness. Most ARCL2D patients exhibit severe hypotonia as well as cardiovascular and neurologic involvement.

OUTRAS DOENÇAS (4)
autosomal recessive cutis laxa type 2Ddevelopmental and epileptic encephalopathy 93undetermined early-onset epileptic encephalopathyautosomal recessive cutis laxa type 2, classic type
HGNC:851UniProt:P38606
AP3B2AP-3 complex subunit beta-2Candidate gene tested inRestrito
FUNÇÃO

Subunit of non-clathrin- and clathrin-associated adaptor protein complex 3 (AP-3) that plays a role in protein sorting in the late-Golgi/trans-Golgi network (TGN) and/or endosomes. The AP complexes mediate both the recruitment of clathrin to membranes and the recognition of sorting signals within the cytosolic tails of transmembrane cargo molecules. AP-3 appears to be involved in the sorting of a subset of transmembrane proteins targeted to lysosomes and lysosome-related organelles. In concert w

LOCALIZAÇÃO

Cytoplasmic vesicle, clathrin-coated vesicle membraneGolgi apparatus

MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 48

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE48 is an autosomal recessive form characterized by onset of seizures in the first year of life. Affected individuals manifest global developmental delay, intellectual disability, absent speech, and poor, if any, motor development.

OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 48undetermined early-onset epileptic encephalopathy
HGNC:567UniProt:Q13367
MT-TKCandidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsFormyl peptide receptors bind formyl peptides and many other ligandsG alpha (q) signalling events
OUTRAS DOENÇAS (4)
mitochondrial diseaseMERRF syndromematernally-inherited cardiomyopathy and hearing lossmaternally-inherited Leigh syndrome
HGNC:7489
MT-THCandidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
Catecholamine biosynthesis
OUTRAS DOENÇAS (4)
mitochondrial diseaseMERRF syndromeMELAS syndromemitochondrial non-syndromic sensorineural hearing loss
HGNC:7487
MT-TS1Candidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsFormyl peptide receptors bind formyl peptides and many other ligandsG alpha (q) signalling events
OUTRAS DOENÇAS (6)
mitochondrial diseaseMERRF syndromepalmoplantar keratoderma-deafness syndromematernally-inherited progressive external ophthalmoplegia
HGNC:7497
MARCHF6E3 ubiquitin-protein ligase MARCHF6Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Endoplasmic reticulum membrane-associated E3 ubiquitin ligase that plays a critical role in mitigating endoplasmic reticulum stress, the regulation of cholesterol and lipid homeostasis, and ferroptosis (PubMed:25088257, PubMed:35941365, PubMed:39216628). Acts as a pivotal component of both the Ac/N-degron pathway (targeting the N-terminal acetyl group of substrates) and the ER-associated protein degradation-cytosol (ERAD-C) pathway (targeting misfolded substrates) (PubMed:30425097, PubMed:359413

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
ER Quality Control Compartment (ERQC)
MECANISMO DE DOENÇA

Epilepsy, familial adult myoclonic, 3

A form of familial myoclonic epilepsy, a neurologic disorder characterized by cortical hand tremors, myoclonic jerks and occasional generalized or focal seizures with a non-progressive or very slowly progressive disease course. Usually, myoclonic tremor is the presenting symptom, characterized by tremulous finger movements and myoclonic jerks of the limbs increased by action and posture. In a minority of patients, seizures are the presenting symptom. Some patients exhibit mild cognitive impairment. FAME3 inheritance is autosomal dominant.

OUTRAS DOENÇAS (2)
epilepsy, familial adult myoclonic, 3benign adult familial myoclonic epilepsy
HGNC:30550UniProt:O60337
STARD7StAR-related lipid transfer protein 7, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May play a protective role in mucosal tissues by preventing exaggerated allergic responses

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (2)
Ubiquinol biosynthesisSynthesis of PC
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
187.9 TPM
Músculo esquelético
153.3 TPM
Cérebro - Hemisfério cerebelar
136.3 TPM
Fibroblastos
125.2 TPM
Tireoide
124.6 TPM
INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (1)
epilepsy, familial adult myoclonic, 2
HGNC:HGNC:18063UniProt:Q9NQZ5
KCNB1Potassium voltage-gated channel subfamily B member 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain, but also in the pancreas and cardiovascular system. Contributes to the regulation of the action potential (AP) repolarization, duration and frequency of repetitive AP firing in neurons, muscle cells and endocrine cells and plays a role in homeostatic attenuation of electrical excitability throughout the brain (PubMed:23161216). Plays also a role in the regulation of exo

LOCALIZAÇÃO

Cell membranePerikaryonCell projection, axonCell projection, dendriteMembranePostsynaptic cell membraneSynapseSynapse, synaptosomeLateral cell membraneCell membrane, sarcolemma

VIAS BIOLÓGICAS (2)
Glucagon-like Peptide-1 (GLP1) regulates insulin secretionVoltage gated Potassium channels
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 26

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE26 patients manifest multiple types of seizures, delayed psychomotor development, poor or absent speech, hypotonia, hypsarrhythmia.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Frontal Cortex BA9
21.0 TPM
Córtex cerebral
16.8 TPM
Esôfago - Muscular
13.9 TPM
Esôfago - Junção
10.7 TPM
Brain Anterior cingulate cortex BA24
8.4 TPM
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 26undetermined early-onset epileptic encephalopathy
HGNC:6231UniProt:Q14721
NPRL2GATOR1 complex protein NPRL2Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Catalytic component of the GATOR1 complex, a multiprotein complex that functions as an inhibitor of the amino acid-sensing branch of the mTORC1 pathway (PubMed:23723238, PubMed:29590090, PubMed:35338845, PubMed:38006878). In response to amino acid depletion, the GATOR1 complex has GTPase activating protein (GAP) activity and strongly increases GTP hydrolysis by RagA/RRAGA (or RagB/RRAGB) within heterodimeric Rag complexes, thereby turning them into their inactive GDP-bound form, releasing mTORC1

LOCALIZAÇÃO

Lysosome membrane

VIAS BIOLÓGICAS (1)
Amino acids regulate mTORC1
EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
68.2 TPM
Cérebro - Hemisfério cerebelar
65.3 TPM
Pituitária
57.7 TPM
Ovário
45.2 TPM
Cervix Endocervix
44.3 TPM
OUTRAS DOENÇAS (2)
epilepsy, familial focal, with variable foci 2familial focal epilepsy with variable foci
HGNC:24969UniProt:Q8WTW4
SAMD12Sterile alpha motif domain-containing protein 12Disease-causing germline mutation(s) inTolerante
LOCALIZAÇÃO

MECANISMO DE DOENÇA

Epilepsy, familial adult myoclonic, 1

A form of familial myoclonic epilepsy, a neurologic disorder characterized by cortical hand tremors, myoclonic jerks and occasional generalized or focal seizures with a non-progressive or very slowly progressive disease course. Usually, myoclonic tremor is the presenting symptom, characterized by tremulous finger movements and myoclonic jerks of the limbs increased by action and posture. In a minority of patients, seizures are the presenting symptom. Some patients exhibit mild cognitive impairment. FAME1 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
8.3 TPM
Brain Frontal Cortex BA9
7.0 TPM
Cerebelo
6.3 TPM
Tireoide
5.8 TPM
Pituitária
5.4 TPM
INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (2)
epilepsy, familial adult myoclonic, 1benign adult familial myoclonic epilepsy
HGNC:31750UniProt:Q8N8I0
TNRC6ATrinucleotide repeat-containing gene 6A proteinDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Plays a role in RNA-mediated gene silencing by both micro-RNAs (miRNAs) and short interfering RNAs (siRNAs). Required for miRNA-dependent repression of translation and for siRNA-dependent endonucleolytic cleavage of complementary mRNAs by argonaute family proteins. As a scaffolding protein, associates with argonaute proteins bound to partially complementary mRNAs, and can simultaneously recruit CCR4-NOT and PAN deadenylase complexes

LOCALIZAÇÃO

Cytoplasm, P-body

VIAS BIOLÓGICAS (10)
Post-transcriptional silencing by small RNAsPre-NOTCH Transcription and TranslationRegulation of PD-L1(CD274) translationRegulation of PTEN mRNA translationCompeting endogenous RNAs (ceRNAs) regulate PTEN translation
MECANISMO DE DOENÇA

Epilepsy, familial adult myoclonic, 6

A form of familial myoclonic epilepsy, a neurologic disorder characterized by cortical hand tremors, myoclonic jerks and occasional generalized or focal seizures with a non-progressive or very slowly progressive disease course. Usually, myoclonic tremor is the presenting symptom, characterized by tremulous finger movements and myoclonic jerks of the limbs increased by action and posture. In a minority of patients, seizures are the presenting symptom. Some patients exhibit mild cognitive impairment. FAME6 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
66.1 TPM
Cerebelo
61.8 TPM
Pituitária
58.6 TPM
Útero
53.5 TPM
Ovário
48.3 TPM
OUTRAS DOENÇAS (2)
epilepsy, familial adult myoclonic, 6benign adult familial myoclonic epilepsy
HGNC:11969UniProt:Q8NDV7
PRDM8PR domain zinc finger protein 8Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Probable histone methyltransferase, preferentially acting on 'Lys-9' of histone H3 (By similarity). Involved in the control of steroidogenesis through transcriptional repression of steroidogenesis marker genes such as CYP17A1 and LHCGR (By similarity). Forms with BHLHE22 a transcriptional repressor complex controlling genes involved in neural development and neuronal differentiation (By similarity). In the retina, it is required for rod bipolar and type 2 OFF-cone bipolar cell survival (By simil

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Regulation of CDH11 gene transcription
MECANISMO DE DOENÇA

Epilepsy, progressive myoclonic 10

A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM10 is an autosomal recessive form characterized by progressive dysarthria, myoclonus, ataxia, cognitive decline, psychosis, dementia and spasticity, with onset in childhood. There is variability between patients.

EXPRESSÃO TECIDUAL(Ubíquo)
Próstata
30.3 TPM
Cervix Ectocervix
27.9 TPM
Esôfago - Junção
25.7 TPM
Brain Frontal Cortex BA9
22.6 TPM
Esôfago - Muscular
21.4 TPM
INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (1)
early-onset Lafora body disease
HGNC:13993UniProt:Q9NQV8
SYNGAP1Ras/Rap GTPase-activating protein SynGAPDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Major constituent of the PSD essential for postsynaptic signaling. Inhibitory regulator of the Ras-cAMP pathway. Member of the NMDAR signaling complex in excitatory synapses, it may play a role in NMDAR-dependent control of AMPAR potentiation, AMPAR membrane trafficking and synaptic plasticity. Regulates AMPAR-mediated miniature excitatory postsynaptic currents. Exhibits dual GTPase-activating specificity for Ras and Rap. May be involved in certain forms of brain injury, leading to long-term lea

LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
Regulation of RAS by GAPs
MECANISMO DE DOENÇA

Intellectual developmental disorder, autosomal dominant 5

A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD5 patients show global developmental delay with delayed motor development, hypotonia, moderate-to-severe intellectual disability, and severe language impairment. Epilepsy and autism can be present in some patients.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
62.9 TPM
Útero
39.4 TPM
Fallopian Tube
38.5 TPM
Ovário
38.3 TPM
Cervix Endocervix
33.9 TPM
OUTRAS DOENÇAS (3)
intellectual disability, autosomal dominant 5epilepsy with myoclonic atonic seizuresundetermined early-onset epileptic encephalopathy
HGNC:11497UniProt:Q96PV0
CPA6Carboxypeptidase A6Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in the proteolytic inactivation of enkephalins and neurotensin in some brain areas. May convert inactive angiotensin I into the biologically active angiotensin II (PubMed:18178555). Releases a C-terminal amino acid, with preference for large hydrophobic C-terminal amino acids and shows only very weak activity toward small amino acids and histidine (PubMed:20855895)

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix

OUTRAS DOENÇAS (4)
familial temporal lobe epilepsy 5febrile seizures, familial, 11familial mesial temporal lobe epilepsygeneralized epilepsy with febrile seizures plus
HGNC:17245UniProt:Q8N4T0
NECAP1Adaptin ear-binding coat-associated protein 1Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Involved in endocytosis

LOCALIZAÇÃO

Cytoplasmic vesicle, clathrin-coated vesicle membraneCell membrane

VIAS BIOLÓGICAS (2)
Clathrin-mediated endocytosisCargo recognition for clathrin-mediated endocytosis
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 21

A severe disease characterized by intractable seizures, profound global developmental delay, and persistent severe axial hypotonia as well as appendicular hypertonia.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
130.3 TPM
Cerebelo
92.7 TPM
Brain Frontal Cortex BA9
78.6 TPM
Pituitária
56.8 TPM
Hipotálamo
53.1 TPM
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 21undetermined early-onset epileptic encephalopathy
HGNC:24539UniProt:Q8NC96
SCN8ASodium channel protein type 8 subunit alphaDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Pore-forming subunit of a voltage-gated sodium channel complex assuming opened or closed conformations in response to the voltage difference across membranes and through which sodium ions selectively pass along their electrochemical gradient (PubMed:24874546, PubMed:25239001, PubMed:25725044, PubMed:26900580, PubMed:29726066, PubMed:33245860, PubMed:36696443, PubMed:36823201). Contributes to neuronal excitability by regulating action potential threshold and propagation (PubMed:24874546, PubMed:2

LOCALIZAÇÃO

Cell membraneCell projection, axonCytoplasmic vesicleCell projection, podosome

VIAS BIOLÓGICAS (2)
Interaction between L1 and AnkyrinsPhase 0 - rapid depolarisation
MECANISMO DE DOENÇA

Cognitive impairment with or without cerebellar ataxia

A disorder characterized by markedly delayed cognitive and motor development, attention deficit disorder, and cerebellar ataxia. Features include bilateral esophoria, strabismatic amblyopia, unsustained gaze evoked nystagmus on horizontal gaze, ataxic gait, dysmetria in the upper limbs and dysarthria, with normal strength, tone, and reflexes.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cerebelo
28.2 TPM
Cérebro - Hemisfério cerebelar
26.4 TPM
Brain Frontal Cortex BA9
17.9 TPM
Córtex cerebral
14.8 TPM
Pituitária
10.9 TPM
OUTRAS DOENÇAS (9)
seizures, benign familial infantile, 5developmental and epileptic encephalopathy, 13myoclonus, familial, 2cognitive impairment with or without cerebellar ataxia
HGNC:10596UniProt:Q9UQD0
SCN2ASodium channel protein type 2 subunit alphaDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient (PubMed:1325650, PubMed:17021166, PubMed:28256214, PubMed:29844171). Implicated in the regulation of hippocampal replay occurring within sharp wave ripples (SPW-R) important for memory (By simi

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
Interaction between L1 and AnkyrinsPhase 0 - rapid depolarisationSensory perception of sweet, bitter, and umami (glutamate) taste
MECANISMO DE DOENÇA

Seizures, benign familial infantile, 3

A form of benign familial infantile epilepsy, a neurologic disorder characterized by afebrile seizures occurring in clusters during the first year of life, without neurologic sequelae. BFIS3 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
70.3 TPM
Cerebelo
65.2 TPM
Brain Frontal Cortex BA9
19.3 TPM
Córtex cerebral
11.5 TPM
Brain Nucleus accumbens basal ganglia
9.1 TPM
OUTRAS DOENÇAS (10)
seizures, benign familial infantile, 3episodic ataxia, type 9developmental and epileptic encephalopathy, 11complex neurodevelopmental disorder
HGNC:10588UniProt:Q99250
PRRT2Proline-rich transmembrane protein 2Disease-causing germline mutation(s) inRestrito
FUNÇÃO

As a component of the outer core of AMPAR complex, may be involved in synaptic transmission in the central nervous system. In hippocampal neurons, in presynaptic terminals, plays an important role in the final steps of neurotransmitter release, possibly by regulating Ca(2+)-sensing. In the cerebellum, may inhibit SNARE complex formation and down-regulate short-term facilitation

LOCALIZAÇÃO

Cell membranePresynaptic cell membraneSynapseCell projection, axonCytoplasmic vesicle, secretory vesicle, synaptic vesicle membranePostsynaptic density membraneCell projection, dendritic spine

MECANISMO DE DOENÇA

Episodic kinesigenic dyskinesia 1

An autosomal dominant form of paroxysmal kinesigenic dyskinesia, a neurologic condition characterized by recurrent and brief attacks of abnormal involuntary movements, triggered by sudden voluntary movement. These attacks usually have onset during childhood or early adulthood and can involve dystonic postures, chorea, or athetosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
606.4 TPM
Cérebro - Hemisfério cerebelar
563.4 TPM
Ovário
183.2 TPM
Brain Frontal Cortex BA9
167.2 TPM
Córtex cerebral
152.5 TPM
OUTRAS DOENÇAS (9)
episodic kinesigenic dyskinesia 1seizures, benign familial infantile, 2infantile convulsions and choreoathetosisfamilial or sporadic hemiplegic migraine
HGNC:30500UniProt:Q7Z6L0
KCNQ3Potassium voltage-gated channel subfamily KQT member 3Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Pore-forming subunit of the voltage-gated potassium (Kv) M-channel which is responsible for the M-current, a key controller of neuronal excitability (PubMed:16319223, PubMed:27564677, PubMed:28793216, PubMed:9872318). M-channel is composed of pore-forming subunits KCNQ2 and KCNQ3 assembled as heterotetramers (PubMed:14534157, PubMed:16319223, PubMed:27564677, PubMed:9872318). The native M-current has a slowly activating and deactivating potassium conductance which plays a critical role in determ

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Interaction between L1 and AnkyrinsVoltage gated Potassium channels
MECANISMO DE DOENÇA

Seizures, benign familial neonatal 2

A disorder characterized by clusters of seizures occurring in the first days of life. Most patients have spontaneous remission by 12 months of age and show normal psychomotor development. The disorder is distinguished from benign familial infantile seizures by an earlier age at onset.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Frontal Cortex BA9
22.6 TPM
Córtex cerebral
18.2 TPM
Brain Anterior cingulate cortex BA24
17.4 TPM
Brain Nucleus accumbens basal ganglia
15.7 TPM
Brain Caudate basal ganglia
11.6 TPM
OUTRAS DOENÇAS (4)
seizures, benign familial neonatal, 2benign neonatal seizuresbenign familial infantile epilepsyjuvenile myoclonic epilepsy
HGNC:6297UniProt:O43525
KCNQ2Potassium voltage-gated channel subfamily KQT member 2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Pore-forming subunit of the voltage-gated potassium (Kv) M-channel which is responsible for the M-current, a key controller of neuronal excitability (PubMed:24277843, PubMed:28793216, PubMed:9836639). M-channel is composed of pore-forming subunits KCNQ2 and KCNQ3 assembled as heterotetramers (PubMed:10781098, PubMed:14534157, PubMed:32884139, PubMed:37857637, PubMed:9836639). The native M-current has a slowly activating and deactivating potassium conductance which plays a critical role in determ

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Interaction between L1 and AnkyrinsVoltage gated Potassium channels
MECANISMO DE DOENÇA

Seizures, benign familial neonatal 1

A disorder characterized by clusters of seizures occurring in the first days of life. Most patients have spontaneous remission by 12 months of age and show normal psychomotor development. Some rare cases manifest an atypical severe phenotype associated with epileptic encephalopathy and psychomotor retardation. The disorder is distinguished from benign familial infantile seizures by an earlier age at onset. In some patients, neonatal convulsions are followed later in life by myokymia, a benign condition characterized by spontaneous involuntary contractions of skeletal muscles fiber groups that can be observed as vermiform movement of the overlying skin. Electromyography typically shows continuous motor unit activity with spontaneous oligo- and multiplet-discharges of high intraburst frequency (myokymic discharges). Some patients may have isolated myokymia.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cerebelo
166.0 TPM
Cérebro - Hemisfério cerebelar
146.5 TPM
Córtex cerebral
68.1 TPM
Brain Frontal Cortex BA9
64.1 TPM
Brain Anterior cingulate cortex BA24
50.1 TPM
OUTRAS DOENÇAS (7)
seizures, benign familial neonatal, 1developmental and epileptic encephalopathy, 7seizures, benign familial infantile, 3malignant migrating partial seizures of infancy
HGNC:6296UniProt:O43526
SLC6A1Sodium- and chloride-dependent GABA transporter 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Mediates transport of gamma-aminobutyric acid (GABA) together with sodium and chloride and is responsible for the reuptake of GABA from the synapse (PubMed:30132828). The translocation of GABA, however, may also occur in the reverse direction leading to the release of GABA (By similarity). The direction and magnitude of GABA transport is a consequence of the prevailing thermodynamic conditions, determined by membrane potential and the intracellular and extracellular concentrations of Na(+), Cl(-

LOCALIZAÇÃO

Cell membranePresynapse

VIAS BIOLÓGICAS (2)
SLC-mediated transport of neurotransmittersReuptake of GABA
MECANISMO DE DOENÇA

Myoclonic-atonic epilepsy

A form of epilepsy characterized by myoclonic-atonic and absence seizures, appearing in early childhood. Patients have delayed development before the onset of seizures and show varying degrees of intellectual disability following seizure onset.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Frontal Cortex BA9
126.4 TPM
Brain Anterior cingulate cortex BA24
120.3 TPM
Córtex cerebral
111.2 TPM
Brain Caudate basal ganglia
105.3 TPM
Brain Nucleus accumbens basal ganglia
90.0 TPM
OUTRAS DOENÇAS (2)
epilepsy with myoclonic atonic seizuresautosomal dominant non-syndromic intellectual disability
HGNC:11042UniProt:P30531
SLC7A6OSProbable RNA polymerase II nuclear localization protein SLC7A6OSDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Directs RNA polymerase II nuclear import

LOCALIZAÇÃO

CytoplasmNucleus

MECANISMO DE DOENÇA

Epilepsy, progressive myoclonic 12

A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM12 is an autosomal recessive form characterized by onset of tonic-clonic seizures and/or myoclonus in the second decade of life. Affected individuals develop cerebellar ataxia associated with progressive cerebral and cerebellar atrophy on brain imaging. Most patients lose ambulation and become wheelchair-bound. Additional more variable features include mild cognitive dysfunction or psychiatric manifestations, such as depression or anxiety.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
17.1 TPM
Fibroblastos
12.7 TPM
Nervo tibial
10.9 TPM
Cervix Endocervix
10.1 TPM
Útero
9.5 TPM
OUTRAS DOENÇAS (1)
epilepsy, progressive myoclonic, 12
HGNC:HGNC:25807UniProt:Q96CW6
CSTBCystatin-BDisease-causing germline mutation(s) inTolerante
FUNÇÃO

This is an intracellular thiol proteinase inhibitor. Tightly binding reversible inhibitor of cathepsins L, H and B

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Neutrophil degranulation
MECANISMO DE DOENÇA

Epilepsy, progressive myoclonic 1

A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM1 is an autosomal recessive form characterized by severe, stimulus-sensitive myoclonus and tonic-clonic seizures. The onset, occurring between 6 and 13 years of age, is characterized by convulsions. Myoclonus begins 1 to 5 years later. The twitchings occur predominantly in the proximal muscles of the extremities and are bilaterally symmetrical, although asynchronous. At first small, they become late in the clinical course so violent that the victim is thrown to the floor. Mental deterioration and eventually dementia develop.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
5317.1 TPM
Vagina
1424.9 TPM
Pulmão
150.1 TPM
Skin Not Sun Exposed Suprapubic
137.0 TPM
Glândula salivar
132.2 TPM
OUTRAS DOENÇAS (2)
Unverricht-Lundborg syndromeautosomal recessive hypohidrotic ectodermal dysplasia
HGNC:2482UniProt:P04080
DEPDC5GATOR1 complex protein DEPDC5Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

As a component of the GATOR1 complex functions as an inhibitor of the amino acid-sensing branch of the mTORC1 pathway (PubMed:23723238, PubMed:25457612, PubMed:29590090, PubMed:29769719, PubMed:31548394, PubMed:35338845). In response to amino acid depletion, the GATOR1 complex has GTPase activating protein (GAP) activity and strongly increases GTP hydrolysis by RagA/RRAGA (or RagB/RRAGB) within heterodimeric Rag complexes, thereby turning them into their inactive GDP-bound form, releasing mTORC1

LOCALIZAÇÃO

Lysosome membraneCytoplasm, cytosolCytoplasm, perinuclear region

VIAS BIOLÓGICAS (1)
Amino acids regulate mTORC1
MECANISMO DE DOENÇA

Epilepsy, familial focal, with variable foci 1

An autosomal dominant form of epilepsy characterized by focal seizures arising from different cortical regions in different family members. Many patients have an aura and show automatisms during the seizures, whereas others may have nocturnal seizures. There is often secondary generalization. Some patients show abnormal interictal EEG, and some patients may have intellectual disability or autism spectrum disorders. Seizure onset usually occurs in the first or second decades, although later onset has been reported, and there is phenotypic variability within families. Penetrance of the disorder is incomplete.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
16.3 TPM
Testículo
13.5 TPM
Linfócitos
10.8 TPM
Baço
10.6 TPM
Cervix Ectocervix
10.5 TPM
OUTRAS DOENÇAS (5)
epilepsy, familial focal, with variable foci 1developmental and epileptic encephalopathy 111familial focal epilepsy with variable fociundetermined early-onset epileptic encephalopathy
HGNC:18423UniProt:O75140
GABRB3Gamma-aminobutyric acid receptor subunit beta-3Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Beta subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (PubMed:14993607, PubMed:18514161, PubMed:22243422, PubMed:22303015, PubMed:24909990, PubMed:26950270, PubMed:30602789). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) (PubMe

LOCALIZAÇÃO

Postsynaptic cell membraneCell membraneCytoplasmic vesicle membrane

VIAS BIOLÓGICAS (2)
GABA receptor activationSignaling by ERBB4
MECANISMO DE DOENÇA

Epilepsy, childhood absence 5

A subtype of idiopathic generalized epilepsy characterized by an onset at age 6-7 years, frequent absence seizures (several per day) and bilateral, synchronous, symmetric 3-Hz spike waves on EEG. Tonic-clonic seizures often develop in adolescence. Absence seizures may either remit or persist into adulthood.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Frontal Cortex BA9
21.5 TPM
Cérebro - Hemisfério cerebelar
16.5 TPM
Brain Nucleus accumbens basal ganglia
15.1 TPM
Pituitária
13.8 TPM
Córtex cerebral
13.7 TPM
OUTRAS DOENÇAS (4)
developmental and epileptic encephalopathy, 43Lennox-Gastaut syndromechildhood absence epilepsyepilepsy, childhood absence, susceptibility to, 5
HGNC:4083UniProt:P28472
CACNA1AVoltage-dependent P/Q-type calcium channel subunit alpha-1ADisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1A gives rise to P and/or Q-type calcium currents. P/Q-type calcium channels belong to the 'high-voltage activated' (HVA) group and are specifically blocked by the spider omega-agatoxin-IVA

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Presynaptic depolarization and calcium channel openingRegulation of insulin secretion
MECANISMO DE DOENÇA

Spinocerebellar ataxia 6

Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA6 is an autosomal dominant cerebellar ataxia (ADCA), mainly caused by expansion of a CAG repeat in the coding region of CACNA1A. There seems to be a correlation between the repeat number and earlier onset of the disorder.

OUTRAS DOENÇAS (9)
migraine, familial hemiplegic, 1episodic ataxia type 2developmental and epileptic encephalopathy, 42spinocerebellar ataxia type 6
HGNC:1388UniProt:O00555
SLC25A12Electrogenic aspartate/glutamate antiporter SLC25A12, mitochondrialDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Mitochondrial electrogenic aspartate/glutamate antiporter that favors efflux of aspartate and entry of glutamate and proton within the mitochondria as part of the malate-aspartate shuttle (PubMed:11566871, PubMed:19641205, PubMed:24515575, PubMed:38945283). Also mediates the uptake of L-cysteinesulfinate (3-sulfino-L-alanine) by mitochondria in exchange of L-glutamate and proton (PubMed:11566871). Can also exchange L-cysteinesulfinate with aspartate in their anionic form without any proton trans

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Aspartate and asparagine metabolismMalate-aspartate shuttle
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 39 with leukodystrophy

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE39 is characterized by global hypomyelination of the central nervous system, with the gray matter appearing relatively unaffected. Inheritance is autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
70.2 TPM
Cérebro - Hemisfério cerebelar
57.9 TPM
Esôfago - Muscular
47.6 TPM
Cerebelo
46.4 TPM
Brain Frontal Cortex BA9
46.4 TPM
OUTRAS DOENÇAS (1)
developmental and epileptic encephalopathy, 39
HGNC:10982UniProt:O75746
GRIN2BGlutamate receptor ionotropic, NMDA 2BDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Component of N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with high calcium permeability and voltage-dependent block by Mg(2+) (PubMed:24272827, PubMed:24863970, PubMed:26875626, PubMed:26919761, PubMed:27839871, PubMed:28095420, PubMed:28126851, PubMed:38538865, PubMed:8768735). Participates in synaptic plasticity for learning and memory formation by contributing to the long-term depression (LTD) of hippocampus membrane currents

LOCALIZAÇÃO

Cell membranePostsynaptic cell membraneCell projection, dendriteLate endosomeLysosomeCytoplasm, cytoskeleton

VIAS BIOLÓGICAS (10)
RAF/MAP kinase cascadeRas activation upon Ca2+ influx through NMDA receptorUnblocking of NMDA receptors, glutamate binding and activationLong-term potentiationNegative regulation of NMDA receptor-mediated neuronal transmission
MECANISMO DE DOENÇA

Intellectual developmental disorder, autosomal dominant 6, with or without seizures

A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD6 additional features may include seizures, hypotonia, abnormal movements, such as dystonia, and autistic features.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Frontal Cortex BA9
6.9 TPM
Brain Nucleus accumbens basal ganglia
5.6 TPM
Córtex cerebral
5.1 TPM
Brain Caudate basal ganglia
4.0 TPM
Brain Anterior cingulate cortex BA24
3.8 TPM
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 27intellectual disability, autosomal dominant 6
HGNC:4586UniProt:Q13224
SLC13A5Na(+)/citrate cotransporterDisease-causing germline mutation(s) inTolerante
FUNÇÃO

High-affinity sodium/citrate cotransporter that mediates the entry of citrate into cells, which is a critical participant of biochemical pathways (PubMed:12445824, PubMed:12826022, PubMed:26324167, PubMed:26384929, PubMed:30054523, PubMed:33597751, PubMed:39622972). May function in various metabolic processes in which citrate has a critical role such as energy production (Krebs cycle), fatty acid synthesis, cholesterol synthesis, glycolysis, and gluconeogenesis (PubMed:12826022). Transports citr

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (1)
SLC-mediated transport of organic anions
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 25, with amelogenesis imperfecta

An autosomal recessive disease characterized by subclinical seizures appearing in the first days of life, evolving to severe epileptic disease. Affected individuals have profound or severe delayed development with lack of speech, and most patients do not acquire the ability to sit. Additional variable features include axial hypotonia, peripheral hypertonia, and abnormal involuntary movements such as dystonia and choreoathetosis. Dental abnormalities, including delayed eruption, hypodontia, tooth hypoplasia, yellow discoloration, thin enamel, and enamel chipping are observed in most patients.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
261.8 TPM
Brain Nucleus accumbens basal ganglia
7.1 TPM
Córtex cerebral
7.0 TPM
Brain Anterior cingulate cortex BA24
6.0 TPM
Brain Frontal Cortex BA9
5.2 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (3)
developmental and epileptic encephalopathy, 25undetermined early-onset epileptic encephalopathyamelocerebrohypohidrotic syndrome
HGNC:23089UniProt:Q86YT5
HCN1Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Hyperpolarization-activated ion channel that are permeable to sodium and potassium ions (PubMed:15351778, PubMed:28086084). Displays lower selectivity for K(+) over Na(+) ions (PubMed:28086084). Contributes to the native pacemaker currents in heart (If) and in the generation of the I(h) current which controls neuron excitability (PubMed:29936235, PubMed:30351409). Participates in cerebellar mechanisms of motor learning (By similarity). May mediate responses to sour stimuli (By similarity)

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (1)
HCN channels
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 24

A disease characterized by early-onset seizures, intellectual disability of varying degrees, and behavioral disturbances or autistic features in most individuals.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Frontal Cortex BA9
9.1 TPM
Cérebro - Hemisfério cerebelar
5.7 TPM
Nervo tibial
5.3 TPM
Córtex cerebral
5.2 TPM
Cerebelo
4.9 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (4)
generalized epilepsy with febrile seizures plus, type 10developmental and epileptic encephalopathy, 24undetermined early-onset epileptic encephalopathygeneralized epilepsy with febrile seizures plus
HGNC:4845UniProt:O60741
KCNMA1Calcium-activated potassium channel subunit alpha-1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+) (PubMed:14523450, PubMed:29330545, PubMed:31152168). It is also activated by the concentration of cytosolic Mg(2+). Its activation dampens the excitatory events that elevate the cytosolic Ca(2+) concentration and/or depolarize the cell membrane. It therefore contributes to repolarization of the membrane potential. Plays a key role in controlling excitability in a number of sys

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (4)
cGMP effectsCa2+ activated K+ channelsAcetylcholine inhibits contraction of outer hair cellsSensory processing of sound by inner hair cells of the cochlea
MECANISMO DE DOENÇA

Paroxysmal non-kinesigenic dyskinesia 3 with or without generalized epilepsy

An autosomal dominant neurologic disorder characterized by absence seizures, generalized tonic-clonic seizures, paroxysmal nonkinesigenic dyskinesia and involuntary dystonic or choreiform movements. Onset is usually in childhood. Patients may have seizures only, dyskinesia only, or both.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
43.8 TPM
Cólon sigmoide
36.4 TPM
Artéria tibial
30.3 TPM
Esôfago - Muscular
29.5 TPM
Esôfago - Junção
29.3 TPM
OUTRAS DOENÇAS (4)
Liang-Wang syndromegeneralized epilepsy-paroxysmal dyskinesia syndromecerebellar atrophy, developmental delay, and seizuresepilepsy, idiopathic generalized, susceptibility to, 16
HGNC:6284UniProt:Q12791
SEMA6BSemaphorin-6BDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Functions as a cell surface repellent for mossy fibers of developing neurons in the hippocampus where it plays a role in axon guidance. May function through the PLXNA4 receptor expressed by mossy cell axons (Microbial infection) Acts as a receptor for P.sordellii toxin TcsL in the in the vascular endothelium

LOCALIZAÇÃO

Cell membrane

MECANISMO DE DOENÇA

Epilepsy, progressive myoclonic 11

A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM11 is an autosomal dominant form. Clinical features include normal or mildly delayed early development, developmental regression after seizures onset, inability to walk, severely impaired intellectual development, poor or absent speech, spasticity, ataxia, and intention tremor. Brain imaging shows cerebellar atrophy in some patients.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Frontal Cortex BA9
91.4 TPM
Córtex cerebral
90.4 TPM
Brain Anterior cingulate cortex BA24
75.3 TPM
Cerebelo
74.9 TPM
Cérebro - Hemisfério cerebelar
72.8 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (2)
epilepsy, progressive myoclonic, 11autosomal dominant non-syndromic intellectual disability
HGNC:10739UniProt:Q9H3T3
KCNC1Voltage-gated potassium channel KCNC1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Voltage-gated potassium channel that opens in response to the voltage difference across the membrane and through which potassium ions pass in accordance with their electrochemical gradient (PubMed:25401298, PubMed:35840580). The mechanism is time-dependent and inactivation is slow (By similarity). Plays an important role in the rapid repolarization of fast-firing brain neurons (By similarity). Can form functional homotetrameric channels and heterotetrameric channels that contain variable proport

LOCALIZAÇÃO

Cell membraneCell projection, axonPresynaptic cell membrane

VIAS BIOLÓGICAS (1)
Voltage gated Potassium channels
MECANISMO DE DOENÇA

Epilepsy, progressive myoclonic 7

A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM7 is an autosomal dominant form characterized by myoclonic epilepsy apparent in the first or second decades of life. Cognitive function may decline in some patients.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cerebelo
92.5 TPM
Cérebro - Hemisfério cerebelar
90.9 TPM
Brain Frontal Cortex BA9
15.4 TPM
Córtex cerebral
13.3 TPM
Brain Anterior cingulate cortex BA24
7.2 TPM
OUTRAS DOENÇAS (1)
progressive myoclonic epilepsy type 7
HGNC:6233UniProt:P48547
CHRNA2Neuronal acetylcholine receptor subunit alpha-2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction. Each nAchR subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensiti

LOCALIZAÇÃO

Synaptic cell membraneCell membrane

VIAS BIOLÓGICAS (2)
Highly calcium permeable nicotinic acetylcholine receptorsHighly calcium permeable postsynaptic nicotinic acetylcholine receptors
MECANISMO DE DOENÇA

Epilepsy, nocturnal frontal lobe, 4

An autosomal dominant focal epilepsy characterized by nocturnal seizures associated with fear sensation, tongue movements, and nocturnal wandering, closely resembling nightmares and sleep walking.

OUTRAS DOENÇAS (2)
autosomal dominant nocturnal frontal lobe epilepsy 4autosomal dominant nocturnal frontal lobe epilepsy
HGNC:1956UniProt:Q15822
MECP2Methyl-CpG-binding protein 2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Chromosomal protein that binds to methylated DNA. It can bind specifically to a single methyl-CpG pair. It is not influenced by sequences flanking the methyl-CpGs. Mediates transcriptional repression through interaction with histone deacetylase and the corepressor SIN3A. Binds both 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC)-containing DNA, with a preference for 5-methylcytosine (5mC)

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (7)
MECP2 regulates transcription of neuronal ligandsRegulation of MECP2 expression and activityMECP2 regulates neuronal receptors and channelsMECP2 regulates transcription factorsTranscriptional Regulation by MECP2
MECANISMO DE DOENÇA

Angelman syndrome

A neurodevelopmental disorder characterized by severe motor and intellectual retardation, ataxia, frequent jerky limb movements and flapping of the arms and hands, hypotonia, seizures, absence of speech, frequent smiling and episodes of paroxysmal laughter, open-mouthed expression revealing the tongue.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
38.8 TPM
Cerebelo
34.5 TPM
Útero
28.9 TPM
Artéria tibial
28.1 TPM
Fallopian Tube
27.9 TPM
OUTRAS DOENÇAS (8)
syndromic X-linked intellectual disability Lubs typeRett syndromeX-linked intellectual disability-psychosis-macroorchidism syndromesevere neonatal-onset encephalopathy with microcephaly
HGNC:6990UniProt:P51608
KCNA2Potassium voltage-gated channel subfamily A member 2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the cardiovascular system. Prevents aberrant action potential firing and regulates neuronal output. Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage differen

LOCALIZAÇÃO

Cell membraneMembraneCell projection, axonSynapseEndoplasmic reticulum membraneCell projection, lamellipodium membraneSynapse, synaptosomePresynaptic cell membraneCell projection, dendriteCell junction, paranodal septate junction

VIAS BIOLÓGICAS (1)
Voltage gated Potassium channels
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 32

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE32 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cerebelo
35.9 TPM
Cérebro - Hemisfério cerebelar
29.5 TPM
Córtex cerebral
19.8 TPM
Brain Frontal Cortex BA9
18.9 TPM
Nervo tibial
12.2 TPM
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 32undetermined early-onset epileptic encephalopathy
HGNC:6220UniProt:P16389
SCARB2Lysosome membrane protein 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Acts as a lysosomal receptor for glucosylceramidase (GBA1) targeting (Microbial infection) Acts as a receptor for enterovirus 71

LOCALIZAÇÃO

Lysosome membrane

VIAS BIOLÓGICAS (1)
Clathrin-mediated endocytosis
MECANISMO DE DOENÇA

Epilepsy, progressive myoclonic 4, with or without renal failure

A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM4 is an autosomal recessive form associated with renal failure in some cases. Cognitive function is preserved.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
119.7 TPM
Fibroblastos
117.7 TPM
Pulmão
114.5 TPM
Cervix Endocervix
105.3 TPM
Artéria coronária
99.7 TPM
OUTRAS DOENÇAS (3)
action myoclonus-renal failure syndromeGaucher disease type IUnverricht-Lundborg syndrome
HGNC:1665UniProt:Q14108
SPTAN1Spectrin alpha chain, non-erythrocytic 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Fodrin, which seems to be involved in secretion, interacts with calmodulin in a calcium-dependent manner and is thus candidate for the calcium-dependent movement of the cytoskeleton at the membrane

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCytoplasm, cell cortex

VIAS BIOLÓGICAS (10)
RAF/MAP kinase cascadeNCAM signaling for neurite out-growthCOPI-mediated anterograde transportInteraction between L1 and AnkyrinsCaspase-mediated cleavage of cytoskeletal proteins
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 5

A disorder characterized by seizures associated with hypsarrhythmia, profound intellectual disability with lack of visual attention and speech development, as well as spastic quadriplegia.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
345.3 TPM
Cerebelo
315.4 TPM
Nervo tibial
201.2 TPM
Brain Frontal Cortex BA9
191.6 TPM
Córtex cerebral
183.4 TPM
OUTRAS DOENÇAS (4)
neuronopathy, distal hereditary motor, autosomal dominant 11developmental and epileptic encephalopathy, 5developmental delay with or without epilepsyspastic paraplegia 91, autosomal dominant, with or without cerebellar ataxia
HGNC:11273UniProt:Q13813
GABRB1Gamma-aminobutyric acid receptor subunit beta-1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Beta subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (PubMed:10449790, PubMed:16412217, PubMed:26950270). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain one or two GABA active binding sites located at the alpha and beta subunit interfaces, depending on subunit composition (By similarity). When activated b

LOCALIZAÇÃO

Postsynaptic cell membraneCell membrane

VIAS BIOLÓGICAS (2)
GABA receptor activationSignaling by ERBB4
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 45

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent.

EXPRESSÃO TECIDUAL(Baixa expressão)
Brain Nucleus accumbens basal ganglia
2.9 TPM
Brain Caudate basal ganglia
2.8 TPM
Pituitária
2.3 TPM
Córtex cerebral
2.3 TPM
Brain Frontal Cortex BA9
2.3 TPM
OUTRAS DOENÇAS (1)
developmental and epileptic encephalopathy, 45
HGNC:HGNC:4081UniProt:P18505
EEF1A2Elongation factor 1-alpha 2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Translation elongation factor that catalyzes the GTP-dependent binding of aminoacyl-tRNA (aa-tRNA) to the A-site of ribosomes during the elongation phase of protein synthesis. Base pairing between the mRNA codon and the aa-tRNA anticodon promotes GTP hydrolysis, releasing the aa-tRNA from EEF1A1 and allowing its accommodation into the ribosome (By similarity). The growing protein chain is subsequently transferred from the P-site peptidyl tRNA to the A-site aa-tRNA, extending it by one amino acid

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Eukaryotic Translation Elongation
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 33

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
2328.3 TPM
Cérebro - Hemisfério cerebelar
972.3 TPM
Cerebelo
934.2 TPM
Coração - Ventrículo esquerdo
786.7 TPM
Brain Frontal Cortex BA9
785.6 TPM
OUTRAS DOENÇAS (4)
developmental and epileptic encephalopathy, 33intellectual disability, autosomal dominant 38undetermined early-onset epileptic encephalopathyautosomal dominant non-syndromic intellectual disability
HGNC:3192UniProt:Q05639
ARXHomeobox protein ARXDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcription factor (PubMed:22194193, PubMed:31691806). Binds to specific sequence motif 5'-TAATTA-3' in regulatory elements of target genes, such as histone demethylase KDM5C (PubMed:22194193, PubMed:31691806). Positively modulates transcription of KDM5C (PubMed:31691806). Activates expression of KDM5C synergistically with histone lysine demethylase PHF8 and perhaps in competition with transcription regulator ZNF711; synergy may be related to enrichment of histone H3K4me3 in regulatory element

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Lissencephaly, X-linked 2

A classic type lissencephaly associated with abnormal genitalia. Patients have severe congenital or postnatal microcephaly, lissencephaly, agenesis of the corpus callosum, neonatal-onset intractable epilepsy, poor temperature regulation, chronic diarrhea, and ambiguous or underdeveloped genitalia.

OUTRAS DOENÇAS (9)
X-linked lissencephaly with abnormal genitaliaPartington syndromecorpus callosum agenesis-abnormal genitalia syndromedevelopmental and epileptic encephalopathy, 1
HGNC:18060UniProt:Q96QS3
TBC1D24TBC1 domain family member 24Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May act as a GTPase-activating protein for Rab family protein(s) (PubMed:20727515, PubMed:20797691). Involved in neuronal projections development, probably through a negative modulation of ARF6 function (PubMed:20727515). Involved in the regulation of synaptic vesicle trafficking (PubMed:31257402)

LOCALIZAÇÃO

Cell membraneCytoplasmCytoplasmic vesicle membranePresynapse

VIAS BIOLÓGICAS (1)
TBC/RABGAPs
MECANISMO DE DOENÇA

Familial infantile myoclonic epilepsy

A subtype of idiopathic epilepsy starting in early infancy and manifesting as myoclonic seizures, febrile convulsions, and tonic-clonic seizures.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
27.8 TPM
Cérebro - Hemisfério cerebelar
26.6 TPM
Brain Frontal Cortex BA9
11.4 TPM
Córtex cerebral
11.2 TPM
Pituitária
9.4 TPM
INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (11)
familial infantile myoclonic epilepsyrolandic epilepsy-paroxysmal exercise-induced dystonia-writer's cramp syndromeautosomal dominant nonsyndromic hearing loss 65autosomal recessive nonsyndromic hearing loss 86
HGNC:29203UniProt:Q9ULP9
KCTD7BTB/POZ domain-containing protein KCTD7Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in the control of excitability of cortical neurons

LOCALIZAÇÃO

Cell membraneCytoplasm, cytosol

VIAS BIOLÓGICAS (2)
Antigen processing: Ubiquitination & Proteasome degradationNeddylation
MECANISMO DE DOENÇA

Epilepsy, progressive myoclonic 3, with or without intracellular inclusions

A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM3 is an autosomal recessive, severe, form with early onset. Multifocal myoclonic seizures begin between 16 and 24 months of age after normal initial development. Neurodegeneration and regression occur with seizure onset. Other features include intellectual disability, dysarthria, truncal ataxia, and loss of fine finger movements. EEG shows slow dysrhythmia, multifocal and occasionally generalized epileptiform discharges. In some patients, ultrastructural findings on skin biopsies identify intracellular accumulation of autofluorescent lipopigment storage material, consistent with neuronal ceroid lipofuscinosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
27.6 TPM
Útero
24.4 TPM
Cervix Ectocervix
23.9 TPM
Brain Spinal cord cervical c-1
23.6 TPM
Testículo
22.7 TPM
OUTRAS DOENÇAS (1)
progressive myoclonic epilepsy type 3
HGNC:21957UniProt:Q96MP8
PRICKLE1Prickle-like protein 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Involved in the planar cell polarity pathway that controls convergent extension during gastrulation and neural tube closure. Convergent extension is a complex morphogenetic process during which cells elongate, move mediolaterally, and intercalate between neighboring cells, leading to convergence toward the mediolateral axis and extension along the anteroposterior axis. Necessary for nuclear localization of REST. May serve as nuclear receptor

LOCALIZAÇÃO

Nucleus membraneCytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Asymmetric localization of PCP proteins
MECANISMO DE DOENÇA

Epilepsy, progressive myoclonic 1B

A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM1B is an autosomal recessive form characterized by myoclonus that progressed in severity over time, tonic-clonic seizures and ataxia.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
15.3 TPM
Cervix Endocervix
10.4 TPM
Útero
8.3 TPM
Cervix Ectocervix
8.0 TPM
Baço
6.5 TPM
OUTRAS DOENÇAS (2)
epilepsy, progressive myoclonic, 1BUnverricht-Lundborg syndrome
HGNC:17019UniProt:Q96MT3
GRIN2AGlutamate receptor ionotropic, NMDA 2ADisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Component of N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with high calcium permeability and voltage-dependent block by Mg(2+) (PubMed:20890276, PubMed:23933818, PubMed:23933819, PubMed:23933820, PubMed:24504326, PubMed:26875626, PubMed:26919761, PubMed:28242877, PubMed:36117210, PubMed:38538865, PubMed:8768735). NMDARs participate in synaptic plasticity for learning and memory formation by contributing to the slow phase of excita

LOCALIZAÇÃO

Cell projection, dendritic spineCell membraneSynapsePostsynaptic cell membraneCytoplasmic vesicle membrane

VIAS BIOLÓGICAS (1)
Assembly and cell surface presentation of NMDA receptors
MECANISMO DE DOENÇA

Epilepsy, focal, with speech disorder and with or without impaired intellectual development

An autosomal dominant, highly variable neurologic disorder. Features range from severe early-onset seizures associated with delayed psychomotor development, persistent speech difficulties, and intellectual disability to a more benign entity characterized by childhood onset of mild or asymptomatic seizures associated with transient speech difficulties followed by remission of seizures in adolescence and normal psychomotor development. The disorder encompasses several clinical entities, including Landau-Kleffner syndrome, epileptic encephalopathy with continuous spike and wave during slow-wave sleep, autosomal dominant rolandic epilepsy, intellectual disability and speech dyspraxia, and benign epilepsy with centrotemporal spikes.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Frontal Cortex BA9
17.0 TPM
Cérebro - Hemisfério cerebelar
14.8 TPM
Cerebelo
12.7 TPM
Córtex cerebral
11.3 TPM
Brain Anterior cingulate cortex BA24
7.2 TPM
OUTRAS DOENÇAS (5)
early-onset epileptic encephalopathy and intellectual disability due to GRIN2A mutationdevelopmental and/or epileptic encephalopathy with spike-wave activation in sleeprolandic epilepsy-speech dyspraxia syndromeself-limited epilepsy with centrotemporal spikes
HGNC:4585UniProt:Q12879
GABRG2Gamma-aminobutyric acid receptor subunit gamma-2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Gamma subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (PubMed:14993607, PubMed:16412217, PubMed:23909897, PubMed:2538761, PubMed:25489750, PubMed:27864268, PubMed:29950725, PubMed:30602789). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit in

LOCALIZAÇÃO

Postsynaptic cell membraneCell membraneCell projection, dendriteCytoplasmic vesicle membrane

VIAS BIOLÓGICAS (2)
GABA receptor activationSignaling by ERBB4
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 74

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE74 is an autosomal dominant form with onset in the first year of life.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
20.3 TPM
Brain Frontal Cortex BA9
19.4 TPM
Cerebelo
15.3 TPM
Córtex cerebral
10.6 TPM
Brain Nucleus accumbens basal ganglia
7.7 TPM
OUTRAS DOENÇAS (7)
febrile seizures, familial, 8developmental and epileptic encephalopathy, 74obsolete Dravet syndromechildhood absence epilepsy
HGNC:4087UniProt:P18507
GOSR2Golgi SNAP receptor complex member 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in transport of proteins from the cis/medial-Golgi to the trans-Golgi network

LOCALIZAÇÃO

Golgi apparatus, cis-Golgi network membraneGolgi apparatus membraneEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
COPII-mediated vesicle transport
MECANISMO DE DOENÇA

Epilepsy, progressive myoclonic 6

A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM6 is an autosomal recessive form characterized by onset of ataxia in the first years of life, followed by action myoclonus and seizures later in childhood, and loss of independent ambulation in the second decade. Cognition is not usually affected, although mild memory difficulties may occur in the third decade.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
21.6 TPM
Pituitária
20.2 TPM
Fibroblastos
16.9 TPM
Cervix Endocervix
16.1 TPM
Linfócitos
15.8 TPM
OUTRAS DOENÇAS (2)
progressive myoclonic epilepsy type 6muscular dystrophy, congenital, with or without seizures
HGNC:4431UniProt:O14653
SCN3ASodium channel protein type 3 subunit alphaDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Pore-forming subunit of Nav1.3, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes. Navs, also called VGSCs (voltage-gated sodium channels) or VDSCs (voltage-dependent sodium channels), operate by switching between closed and open conformations depending on the voltage difference across the membrane. In the open conformation they allow Na(+) ions to selectively pass through the pore, along their electrochemical gradient.

LOCALIZAÇÃO

Cell membraneBasal cell membrane

VIAS BIOLÓGICAS (3)
Interaction between L1 and AnkyrinsPhase 0 - rapid depolarisationSensory perception of sweet, bitter, and umami (glutamate) taste
MECANISMO DE DOENÇA

Epilepsy, familial focal, with variable foci 4

An autosomal dominant form of epilepsy characterized by focal seizures arising from different cortical regions, including the temporal, frontal, parietal, and occipital lobes. Seizure types commonly include temporal lobe epilepsy, frontal lobe epilepsy, and nocturnal frontal lobe epilepsy. Some patients may have intellectual disability or autism spectrum disorders. Seizure onset usually occurs in the first or second decades, although later onset has been reported, and there is phenotypic variability within families. A subset of patients have structural brain abnormalities. Penetrance of the disorder is incomplete. FFEVF4 is characterized by onset of focal seizures in the first years of life.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
13.0 TPM
Cerebelo
11.3 TPM
Hipotálamo
9.3 TPM
Brain Nucleus accumbens basal ganglia
8.5 TPM
Pituitária
8.1 TPM
OUTRAS DOENÇAS (5)
epilepsy, familial focal, with variable foci 4developmental and epileptic encephalopathy, 62genetic developmental and epileptic encephalopathyfamilial focal epilepsy with variable foci
HGNC:10590UniProt:Q9NY46
SERPINI1NeuroserpinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Serine protease inhibitor that inhibits plasminogen activators and plasmin but not thrombin (PubMed:11880376, PubMed:19265707, PubMed:19285087, PubMed:26329378, PubMed:9442076). May be involved in the formation or reorganization of synaptic connections as well as for synaptic plasticity in the adult nervous system. May protect neurons from cell damage by tissue-type plasminogen activator (Probable)

LOCALIZAÇÃO

SecretedCytoplasmic vesicle, secretory vesicle lumenPerikaryon

MECANISMO DE DOENÇA

Encephalopathy, familial, with neuroserpin inclusion bodies

A neurodegenerative disease clinically characterized by dementia. Additional features include intellectual decline, psychic seizures, progressive myoclonic epilepsy, and cerebral atrophy. Histologically, it is characterized by the presence of eosinophilic inclusion bodies (called Collins bodies) throughout the deeper layers of the cerebral cortex, leading to neuronal death.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Frontal Cortex BA9
270.5 TPM
Brain Spinal cord cervical c-1
162.0 TPM
Córtex cerebral
133.3 TPM
Brain Anterior cingulate cortex BA24
120.6 TPM
Hipotálamo
71.8 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (2)
familial encephalopathy with neuroserpin inclusion bodiesprogressive dementia with neuroserpin inclusion bodies
HGNC:8943UniProt:Q99574
NHLRC1E3 ubiquitin-protein ligase NHLRC1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

E3 ubiquitin-protein ligase. Together with the phosphatase EPM2A/laforin, appears to be involved in the clearance of toxic polyglucosan and protein aggregates via multiple pathways. In complex with EPM2A/laforin and HSP70, suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system (UPS). Ubiquitinates the glycogen-targeting protein phosphatase subunits PPP1R3C/PTG and PPP1R3D in a laforin-dependent manner and targets them for pro

LOCALIZAÇÃO

Endoplasmic reticulumNucleus

VIAS BIOLÓGICAS (1)
Glycogen synthesis
MECANISMO DE DOENÇA

Myoclonic epilepsy of Lafora 2

A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. MELF2 is an autosomal recessive, severe form characterized by onset of progressive neurodegeneration between 8 and 18 years of age. Initial features can include headache, myoclonic jerks, generalized seizures, and often visual hallucination. Typically, as seizures increase in frequency, cognitive function declines towards dementia, and affected individuals die usually within 10 years after onset. At the cellular level, MELF2 is characterized by accumulation of starch-like polyglucosans called Lafora bodies (LBs) that are most abundant in organs with the highest glucose metabolism: brain, heart, liver and skeletal muscle.

EXPRESSÃO TECIDUAL(Baixa expressão)
Skin Sun Exposed Lower leg
5.0 TPM
Skin Not Sun Exposed Suprapubic
4.6 TPM
Brain Frontal Cortex BA9
3.9 TPM
Fibroblastos
3.7 TPM
Córtex cerebral
3.4 TPM
OUTRAS DOENÇAS (2)
myoclonic epilepsy of Lafora 2Lafora disease
HGNC:21576UniProt:Q6VVB1

Medicamentos e terapias

LAMOTRIGINEPhase 4

Mecanismo: Sodium channel alpha subunit blocker

RUFINAMIDEPhase 4

Mecanismo: Sodium channel alpha subunit blocker

CANNABIDIOLPhase 4

Mecanismo: Cannabinoid CB1 receptor negative allosteric modulator

TOPIRAMATEPhase 4

Mecanismo: Sodium channel alpha subunit blocker

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

284 variantes patogênicas registradas no ClinVar.

🧬 EPM2A: NM_005670.4(EPM2A):c.934del (p.Arg312fs) ()
🧬 EPM2A: NM_005670.4(EPM2A):c.361G>T (p.Val121Leu) ()
🧬 EPM2A: GRCh38/hg38 6q24.2-27(chr6:144488859-170610382)x3 ()
🧬 EPM2A: NM_005670.4(EPM2A):c.920_921dup (p.Glu308fs) ()
🧬 EPM2A: Single allele ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 1,713 variantes classificadas pelo ClinVar.

86
257
1370
Patogênica (5.0%)
VUS (15.0%)
Benigna (80.0%)
VARIANTES MAIS SIGNIFICATIVAS
CNTNAP2: NM_014141.6(CNTNAP2):c.2025_2026insCAGT (p.Thr676fs) [Pathogenic]
CNTNAP2: NM_014141.6(CNTNAP2):c.3599C>T (p.Ser1200Leu) [Uncertain significance]
CNTNAP2: NM_014141.6(CNTNAP2):c.638C>A (p.Ala213Asp) [Uncertain significance]
CNTNAP2: NM_014141.6(CNTNAP2):c.1657G>A (p.Ala553Thr) [Uncertain significance]
CNTNAP2: NM_014141.6(CNTNAP2):c.123T>A (p.Ser41=) [Likely benign]

Vias biológicas (Reactome)

172 vias biológicas associadas aos genes desta condição.

Myoclonic epilepsy of Lafora PPARA activates gene expression Transcriptional regulation of white adipocyte differentiation RSV-host interactions GABA receptor activation Cytosolic tRNA aminoacylation Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor RAF/MAP kinase cascade Neurexins and neuroligins Synaptic adhesion-like molecules Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation Cellular hexose transport Vitamin C (ascorbate) metabolism Regulation of insulin secretion Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1) Lactose synthesis Oxidative Stress Induced Senescence FCERI mediated MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 Activation of the AP-1 family of transcription factors PLC beta mediated events Synthesis of IP3 and IP4 in the cytosol Acetylcholine regulates insulin secretion Ca2+ pathway G alpha (q) signalling events G beta:gamma signalling through PLC beta Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion Presynaptic function of Kainate receptors Cation-coupled Chloride cotransporters EPHB-mediated forward signaling Interaction between L1 and Ankyrins Phase 0 - rapid depolarisation Mechanical load activates signaling by PIEZO1 and integrins in osteocytes Toll Like Receptor 4 (TLR4) Cascade Retrograde neurotrophin signalling Gap junction degradation Formation of annular gap junctions MHC class II antigen presentation EPH-ephrin mediated repulsion of cells Recycling pathway of L1 Clathrin-mediated endocytosis HATs acetylate histones Formation of WDR5-containing histone-modifying complexes Amino acids regulate mTORC1 NGF-independant TRKA activation Adenosine P1 receptors G alpha (s) signalling events Surfactant metabolism Interferon gamma signaling Activation of BAD and translocation to mitochondria Translocation of SLC2A4 (GLUT4) to the plasma membrane Regulation of PLK1 Activity at G2/M Transition Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Anchoring of the basal body to the plasma membrane RHO GTPases activate PKNs TP53 Regulates Metabolic Genes Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex AURKA Activation by TPX2 Regulation of localization of FOXO transcription factors SARS-CoV-1 targets host intracellular signalling and regulatory pathways SARS-CoV-2 targets host intracellular signalling and regulatory pathways Transcriptional and post-translational regulation of MITF-M expression and activity SPOP-mediated proteasomal degradation of PD-L1(CD274) Voltage gated Potassium channels Glucagon-like Peptide-1 (GLP1) regulates insulin secretion ROS and RNS production in phagocytes Insulin receptor recycling Transferrin endocytosis and recycling Ion channel transport Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy Regulation of CDH11 Expression and Function Regulation of CDH11 gene transcription Transcriptional regulation by RUNX3 TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Cell Death Genes Defective homologous recombination repair (HRR) due to PALB2 loss of function Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function NPAS4 regulates expression of target genes Intracellular oxygen transport Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Defective MUTYH substrate processing Defective Base Excision Repair Associated with NEIL1 Signaling by MET Virion Assembly and Release Virion Assembly and Release IKK complex recruitment mediated by RIP1 Transcriptional regulation by RUNX1 Mitochondrial unfolded protein response (UPRmt) NADE modulates death signalling Activation of BIM and translocation to mitochondria Activation of caspases through apoptosome-mediated cleavage Ubiquinol biosynthesis Export of Viral Ribonucleoproteins from Nucleus NEP/NS2 Interacts with the Cellular Export Machinery ER Quality Control Compartment (ERQC) Synthesis of PC Mitochondrial protein degradation Pre-NOTCH Transcription and Translation Oncogene Induced Senescence Post-transcriptional silencing by small RNAs Transcriptional regulation by small RNAs MAPK6/MAPK4 signaling Transcriptional Regulation by VENTX Regulation of RUNX1 Expression and Activity RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function Regulation of PTEN mRNA translation Competing endogenous RNAs (ceRNAs) regulate PTEN translation Transcriptional Regulation by MECP2 Estrogen-dependent gene expression Regulation of MECP2 expression and activity NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux Regulation of CDH11 mRNA translation by microRNAs Regulation of CDH1 mRNA translation by microRNAs Regulation of NPAS4 mRNA translation Regulation of MITF-M-dependent genes involved in apoptosis TGFBR3 expression Regulation of PD-L1(CD274) translation Regulation of RAS by GAPs Golgi Associated Vesicle Biogenesis Cargo recognition for clathrin-mediated endocytosis Sensory perception of sweet, bitter, and umami (glutamate) taste SLC-mediated transport of neurotransmitters Reuptake of GABA Neutrophil degranulation Signaling by ERBB4 Presynaptic depolarization and calcium channel opening Mitochondrial protein import Aspartate and asparagine metabolism Malate-aspartate shuttle MECP2 regulates neuronal receptors and channels Activated NTRK2 signals through FYN SLC-mediated transport of organic anions HCN channels Ca2+ activated K+ channels cGMP effects Sensory processing of sound by inner hair cells of the cochlea Acetylcholine inhibits contraction of outer hair cells Highly calcium permeable postsynaptic nicotinic acetylcholine receptors Highly calcium permeable nicotinic acetylcholine receptors Loss of MECP2 binding ability to 5hmC-DNA Loss of phosphorylation of MECP2 at T308 Loss of MECP2 binding ability to the NCoR/SMRT complex Loss of MECP2 binding ability to 5mC-DNA MECP2 regulates transcription of neuronal ligands MECP2 regulates transcription factors MECP2 regulates transcription of genes involved in GABA signaling Nuclear events stimulated by ALK signaling in cancer Caspase-mediated cleavage of cytoskeletal proteins Nephrin family interactions NCAM signaling for neurite out-growth COPI-mediated anterograde transport RHOU GTPase cycle RHOV GTPase cycle Sensory processing of sound by outer hair cells of the cochlea Eukaryotic Translation Elongation SLIT2 gene expression is stimulated by ISL1 Primary multipotent pancreatic progenitor cell produces trunk bipotent pancreatic progenitor cell TBC/RABGAPs Neddylation Antigen processing: Ubiquitination & Proteasome degradation Asymmetric localization of PCP proteins COPII-mediated vesicle transport XBP1(S) activates chaperone genes Cargo concentration in the ER Intra-Golgi traffic Glycogen synthesis

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado4
3Fase 31
2Fase 22
1Fase 11
·Pré-clínico6
Medicamentos catalogadosEnsaios clínicos· 4 medicamentos · 10 ensaios
✓ Aprovados — podem ser usados hoje
LAMOTRIGINERUFINAMIDECANNABIDIOLTOPIRAMATE
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Síndrome epiléptico

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

5 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

316 ensaios clínicos encontrados, 9 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
975 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 975

#1

Patterns of Response to Treatment and Outcome of Childhood Absence Epilepsy: A Multicenter Study From Saudi Arabia.

Pediatric neurology2026 Mar 06

Childhood absence epilepsy (CAE) is a common pediatric epilepsy syndrome affecting school-aged children. While generally considered benign, recent studies indicate that a significant proportion of patients experience pharmaco-resistance and neuropsychiatric comorbidities. This study aimed to investigate the outcomes of CAE patients across tertiary care centers in Saudi Arabia. A retrospective cohort study was conducted at multiple tertiary care centers in Saudi Arabia. The study included 61 pediatric patients (≤14 years) with confirmed CAE diagnosis. Data were collected from electronic medical records. Response to treatment was defined as >50% reduction in seizure frequency from the baseline, while terminal remission was defined as one-year seizure-free off antiseizure medications. The study population had an equal gender distribution (50.8% male) with a median age of 7 years at diagnosis. Most patients (93.4%) had no comorbidities. The majority (88.5%) achieved response to appropriate antiseizure medications; of these responders, 27.8% achieved terminal remission, while 11.5% demonstrated no response. Isolated staring episodes were the predominant presentation (88.5%). Most patients (93.4%) were managed with monotherapy, with valproic acid (60.7%) being the most commonly prescribed medication, followed by ethosuximide (36.1%). Age at diagnosis showed a positive association with recurrence risk, though not statistically significant. CAE patients in Saudi Arabian tertiary care centers demonstrate favorable outcomes, with high response rates with monotherapy. Early diagnosis and treatment may improve prognosis, as suggested by the trend toward higher recurrence rates in patients diagnosed at older ages.

#2

Investigation of adolescent cases diagnosed with idiopathic/genetic generalized epilepsy in terms of self-esteem, aggression, body perception, and alexithymia.

European journal of pediatrics2026 Mar 19

This study examined self-esteem, body image, alexithymia, and aggression in adolescents with idiopathic/genetic generalized epilepsy (IGE). These domains were selected because they may be affected not only by epilepsy itself but also by stigma, difficulties in emotional regulation, or treatment-related effects. Assessing these domains together was intended to examine whether IGE might be associated with additional psychosocial strain in otherwise clinically stable adolescents. We carried out a case-control study including 45 adolescents with IGE and 45 controls matched for age and sex. Controls were selected from outpatient services and were required to have no neurological disorders. Psychiatric disorders were assessed using the K-SADS (Kiddie Schedule for Affective Disorders and Schizophrenia) interview; no clinically significant psychiatric diagnoses were identified in the control group. All participants completed standardized Turkish questionnaires on the same day.Within the epilepsy group, 20.0% were diagnosed with juvenile absence epilepsy (JAE), 22.2% with juvenile myoclonic epilepsy (JME), and 57.8% with epilepsy with generalized tonic-clonic seizures alone (EGTCSA). Across all four psychological measures, the epilepsy and control groups showed no statistically significant differences (all p > 0.05). No significant differences were found in subgroup analyses based on epilepsy syndrome or seizure frequency. Adolescents with well-controlled IGE and minimal psychiatric comorbidities demonstrated comparable levels of psychosocial functioning to their healthy peers. This finding is consistent with evidence suggesting that psychosocial difficulties in epilepsy are often linked to comorbidity and contextual factors rather than to the diagnosis alone. Studies conducted in broader settings and with larger, more varied samples will be needed to better understand how medical, emotional, and environmental factors jointly influence psychosocial outcomes in this population. • Adolescents with epilepsy are frequently considered at increased risk for psychosocial difficulties, including lower self-esteem, emotional instability, and body image concerns. • In this study, no significant differences were found in self-esteem, body image, alexithymia, or aggression among Turkish adolescents with idiopathic/genetic generalized epilepsy compared with healthy controls. These findings suggest that, when seizures are well controlled and psychiatric comorbidities are limited, epilepsy itself may not confer additional psychosocial vulnerability.

#3

From clinical practice to mechanistic insights in ketogenic diets for epilepsy.

The Lancet. Neurology2026 Mar 11

Ketogenic diet therapies, including the classic ketogenic diet, modified Atkins diet, and low glycaemic index treatment, have shown effectiveness in controlling seizures, in part by shifting metabolism from glucose to ketone bodies. They improve mitochondrial function, reduce neuroinflammation, and modulate neurotransmitters. Ketogenic diet therapies also affect the gut microbiome, potentially impacting neurotransmitter balance in ways that contribute to seizure control. A classic ketogenic diet is effective yet restrictive, whereas the modified Atkins diet and low glycaemic index treatment offer greater flexibility, tolerability, and ease of implementation, particularly in resource-limited settings. Cochrane reviews and meta-analyses rank the certainty of randomised controlled trial evidence for ketogenic diet therapies as limited. Early initiation of ketogenic diet therapies, particularly in children or patients with metabolic epilepsies, improves seizure outcomes, potentially preventing further mitochondrial and neuronal damage and reducing the risk of developing resistance to antiseizure medications. Research using rigorous, large-scale comparative effectiveness study designs that accounts for differences in age, epilepsy type, dietary therapy modality, sociodemographic background, care delivery contexts, and that minimises performance and observation bias is needed to resolve remaining uncertainties regarding the efficacy and real-world challenges of ketogenic diet therapies in epilepsy.

#4

[Febrile infection-related epilepsy syndrome (FIRES) with the claustrum sign in a 55-year-old woman: a case report].

Rinsho shinkeigaku = Clinical neurology2026 Mar 11

A 55-year-old woman presented to our clinic with refractory status epilepticus, which developed after her symptoms of influenza had initially improved. Despite various tests, the definite cause could not be identified; however, her clinical presentation preceded by a febrile infection was consistent with that of febrile infection-related epilepsy syndrome (FIRES), a subtype of new-onset refractory status epilepticus (NORSE). Because the brain MRI on day seven revealed a claustrum sign, we administered aggressive immunotherapy. Thereafter, the patient recovered from status epilepticus, and the claustrum sign disappeared on brain MRI. Although the retrograde amnesia and chronic epilepsy persisted, the patient recovered and was able to live at home upon discharge. In patients with refractory status epilepticus that develops after a preceding infection, FIRES should be considered in the differential diagnosis regardless of age at onset, and early aggressive immunotherapy should be considered, especially in patients with a claustrum sign.

#5

Epilepsy Phenotypic Spectrum of NUS1-Related Disorder: A Case Series.

Annals of the Child Neurology Society2026 Jan 21

Epilepsy with myoclonic and atonic seizures (EMAtS), also known as Doose syndrome, accounts for 1%-2% of childhood epilepsies, and various genes have been implicated in causing this epilepsy syndrome. NUS1 encodes for Nogo-B receptor (NgBR), which stabilizes the dehydrodolichyl-diphosphate synthase complex in the endoplasmic reticulum, promoting its enzymatic activity (cis-IPTase) and thereby regulating cholesterol biosynthesis. Pathogenic variants in NUS1 have been associated with movement disorder and epilepsy; however, the spectrum of epilepsy and electroencephalogram (EEG) phenotype has not been well characterized. We describe a single-center case series of five patients with NUS1-related disorder. In our cohort, three patients met the diagnostic criteria of EMAtS, and the remainder had a milder form of generalized epilepsy. Four patients had a pathogenic variant in NUS1 on one allele, and one patient had a missense change of unclear significance but fit the phenotype of NUS1-related disorder. All patients bearing the pathogenic variants in NUS1 had normal to mild developmental delay at the onset of epilepsy, with normal brain magnetic resonance imaging. Age of seizure onset in these patients was 1-7 years, and patients responded to levetiracetam and/or valproic acid. The EEG findings for these patients included the presence of spike and slow wave discharges, as well as the presence of generalized, invariant monomorphic theta range activity in the awake state, which was seen in four out of the five patients. Taken together, NUS1 variants are associated with generalized epilepsy phenotype and an invariant EEG pattern of monomorphic theta activity.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC337 artigos no totalmostrando 199

2026

Patterns of Response to Treatment and Outcome of Childhood Absence Epilepsy: A Multicenter Study From Saudi Arabia.

Pediatric neurology
2026

Investigation of adolescent cases diagnosed with idiopathic/genetic generalized epilepsy in terms of self-esteem, aggression, body perception, and alexithymia.

European journal of pediatrics
2026

From clinical practice to mechanistic insights in ketogenic diets for epilepsy.

The Lancet. Neurology
2026

[Febrile infection-related epilepsy syndrome (FIRES) with the claustrum sign in a 55-year-old woman: a case report].

Rinsho shinkeigaku = Clinical neurology
2026

Diagnostic reassessment in patients previously diagnosed with childhood-onset epilepsy during the transition to adult care: A retrospective cohort study in a tertiary epilepsy center.

Epilepsia open
2026

Metabolism-corrected propofol exposure intensity and long-term intelligence quotient in pediatric febrile infection-related epilepsy syndrome: a retrospective cohort study.

Frontiers in medicine
2026

Proteomic Studies in Absence Epilepsy: A Systematic Review of Methodological Diversity and Implications for Data Interpretation.

Current issues in molecular biology
2026

Evaluating executive functions in children and adolescents with epilepsy using the EpiTRACK tool: A 5-year longitudinal follow-up study.

Epilepsy & behavior : E&B
2026

Epilepsy Phenotypic Spectrum of NUS1-Related Disorder: A Case Series.

Annals of the Child Neurology Society
2026

An increase in cerebrospinal fluid macrophage migration inhibitory factor levels in pediatric patients with acute neuroinflammatory diseases: A preliminary study.

Brain & development
2026

Peculiar Clinical Manifestation in a Child With Self-Limited Epilepsy With Autonomic Seizures (SeLEAS) Presenting in an All-Four Position: A Case Report.

Case reports in neurological medicine
2026

Influence of epilepsy syndrome on cancer comorbidity.

Epilepsy & behavior : E&B
2026

Extreme cryptogenic new onset refractory status epilepticus/febrile infection-related epilepsy syndrome: Evidence of profound neuroinflammation and neuronal injury.

Epilepsia
2026

Case Report: Management of Hemiconvulsion Hemiplegic Epilepsy Syndrome Utilizing Ketamine and Ketogenic Diet.

Pediatric neurology
2026

Pediatric new-onset super refractory status epilepticus: Potential of timely immunotherapy in a resource-limited PICU.

Seizure
2026

[Expert consensus on the diagnosis and treatment of pediatric febrile infection-related epilepsy syndrome (2026)].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2026

Hemiconvulsion-hemiplegia-epilepsy syndrome in adults - clinical case of a 28-year-old female patient with a history of drug abuse.

Neurologia i neurochirurgia polska
2026

Status Epilepticus in Children With Hemophagocytic Lymphohistiocytosis: Literature Review.

Journal of child neurology
2026

Secondary hemophagocytic lymphohistiocytosis concurrent with febrile infection-related epilepsy syndrome in a child.

Seizure
2026

Efficacy differences between tocilizumab and ketogenic diet during acute phase of febrile Infection-Related epilepsy syndrome in children: A retrospective cohort study.

Epilepsy & behavior : E&B
2026

Base editing rescues seizures and sudden death in a SCN8A mutation-associated developmental epileptic encephalopathy model.

The Journal of clinical investigation
2026

Sleep disturbances in children and adolescents with epilepsy: Clinical, polysomnographic and management aspects.

Sleep medicine
2026

Intellectual function and psychiatric comorbidities in patients with epilepsy with eyelid myoclonia.

Epilepsy & behavior : E&B
2026

The role of social context in cognitive and neurobehavioural outcomes in epilepsy.

Nature reviews. Neurology
2026

Hemiconvulsion-Hemiplegia-Epilepsy Syndrome Associated with SARS-CoV-2 Infection and a Heterozygous IRF3 Variant in a 10-month-old Girl: A Case Report.

Neuropediatrics
2026

Clinical features associated with a response to ethosuximide in developmental and epileptic encephalopathy with spike wave activation in sleep.

Epilepsy & behavior : E&B
2026

Biomarker discovery in Lennox-Gastaut syndrome: Advances and challenges in electrophysiological, genetic, neuroimaging, and neuroinflammatory approaches.

Epilepsy & behavior : E&B
2026

Febrile infection-related epilepsy syndrome (FIRES) in adults: a case report and review of factors associated with survival.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

White matter structure-function decoupling in juvenile myoclonic epilepsy.

NeuroImage. Clinical
2026

Hemiconvulsion-hemiplegia-epilepsy syndrome in a child with an underlying hypomyelinating leukodystrophy: a previously unreported association.

Pediatric radiology
2025

Lidocaine as a potential anti-seizure therapy for pediatric FIRES: a promising therapeutic approach.

Frontiers in pediatrics
2025

Ketogenic Diet Therapy for Adult Febrile Infection-Related Epilepsy Syndrome (FIRES): A Case Series of Five Patients and Clinical Efficacy Analysis.

Infection and drug resistance
2025

Status Epilepsy Syndromes Made Easy: Pediatric Perspectives.

Children (Basel, Switzerland)
2026

Dravet Syndrome Patient-Derived Neural Cells Present Altered Levels of Potassium, Copper, and Zinc.

ACS chemical neuroscience
2025

The symmetrical claustrum sign in pediatric febrile infection-related epilepsy syndrome: Diagnostic value and clinical implications.

Epilepsia
2026

Tocilizumab for super-refractory status epilepticus in children with FIRES: A case series.

Seizure
2025

Clinical and genetics spectrum of 392 Chinese patients with genetic epilepsy with febrile seizures plus.

Journal of neurology
2026

Elevated thalamic blood flow in self-limited epilepsy with centrotemporal spikes.

Epilepsy research
2025

Case Report: Successful multimodal management of FIRES in a pediatric patient using anakinra, ketogenic diet, and induced hypothermia.

Frontiers in pediatrics
2026

Long-term administration of EQU-001 (ivermectin) suppresses spasms in a rat model of infantile epileptic spasms syndrome.

Epilepsy research
2026

Modified atkins diet in children with developmental and epileptic encephalopathy with spike-wave activation in sleep (D/EE-SWAS): A prospective interventional, non-randomized, single-arm study.

Seizure
2026

Beyond Anakinra and Tocilizumab: Additional Adjunctive Therapies in Pediatric New Onset Refractory Status Epilepticus and Febrile Infection-Related Epilepsy Syndrome - A Narrative Review.

Pediatric neurology
2025

Genotypic and phenotypic analysis of epilepsy associated with NPRL2/NPRL3 genes.

Seizure
2025

Intelligence outcomes in 17 patients with developmental and/or epileptic encephalopathy with spike-wave activation in sleep ((D)EE-SWAS) after remission of SWAS.

Epilepsy & behavior : E&B
2026

α-Asaronol, a low-toxicity α-asarone metabolite, suppresses seizures in zebrafish Dravet syndrome via positive modulation of GABAA receptors and LDH inhibition.

Neuropharmacology
2026

Clinical and genetic landscape of epilepsies with absence seizures and single-gene etiology.

Epilepsia
2026

Dravet syndrome diagnosed in adults.

Practical neurology
2025

The spectrum of pediatric acute leukoencephalopathy with restricted diffusion presenting as febrile infection-related refractory epilepsy syndrome.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
2025

A Case Report of Bartonella henselae-Related New-Onset Refractory Status Epilepticus / Febrile Infection-Related Epilepsy Syndrome Complicated With Stimulus-Induced Rhythmic, Periodic, or Ictal Discharges.

Journal of child neurology
2026

The interacting etiologies of hippocampal sclerosis in epilepsy: A scoping review.

Epilepsia
2025

Study on brain functional networks and wearable device monitoring in children with SeLECTs and high spike-wave index (SWI >50%).

Frontiers in neurology
2025

Rediscovering parainfectious encephalopathy in the post-COVID-19 era.

Frontiers in immunology
2025

Developmental and epileptic encephalopathy with spike-wave activation in sleep (D/EE-SWAS): Clinical and treatment insights from a cohort of 50 children.

Seizure
2025

Febrile Infection-Related Epilepsy Syndrome (FIRES) in a Young Adult: A Case Report Highlighting Advanced Neuroimaging.

Clinical neuroradiology
2025

Vagus nerve stimulation combined with ketogenic diet versus ketogenic diet alone in the treatment of febrile infection-related epilepsy syndrome in children: efficacy and long-term prognosis study.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2025

Haploinsufficiency of brain-specific kinase BRSK1 causes epilepsy and neurodevelopmental disorders.

Epilepsia
2025

Prenatal betamethasone-postnatal N-methyl-D-aspartic acid model of spasms: Update on mechanisms and treatments.

Epilepsia open
2025

De novo pathogenic CSF1R variant implicates microglial dysfunction in pathogenesis of febrile infection-related epilepsy syndrome.

Epilepsia
2025

Interictal activity fluctuations follow rather than precede seizures on multiple time scales in a mouse model of focal cortical dysplasia.

Neurobiology of disease
2025

Long-term seizure outcomes and the likelihood of antiseizure medication withdrawal in patients with juvenile absence epilepsy: A 10-year follow-up study.

Seizure
2026

Quality of life over time after new onset refractory status epilepticus.

Epilepsia
2025

Cortical versus hippocampal network dysfunction in a human brain assembloid model of epilepsy and intellectual disability.

Cell reports
2025

Recessive TMEM167A variants cause neonatal diabetes, microcephaly, and epilepsy syndrome.

The Journal of clinical investigation
2025

Increased volumes of the precuneus and the pallidum in idiopathic generalized epilepsy.

Scientific reports
2025

A survey of adult caregivers of people with developmental and epileptic encephalopathies: A long-term care planning needs assessment.

Epilepsy & behavior : E&B
2025

Human herpes virus-7-related severe encephalitis diagnosed using mNGS in immunocompetent pediatric patients.

Virology journal
2025

Standard complete blood count to predict long-term outcomes in febrile infection-related epilepsy syndrome (FIRES): A multicenter study.

Epilepsia
2025

Gastrointestinal symptoms are common in patients with new-onset refractory status epilepticus (NORSE).

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

Update in new-onset refractory status epilepticus and febrile infection-related epilepsy syndrome.

Current opinion in pediatrics
2025

[Febrile infection-related epilepsy syndrome].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
2025

Frontiers in EEG as a tool for the management of pediatric epilepsy: Past, present, and future.

Epilepsia open
2025

Epilepsy with eyelid myoclonia: A systematic review and meta-analysis.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2025

CSF IL-6 in children with neuroinflammatory conditions.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
2025

Immune dysregulation in new-onset refractory status epilepticus (NORSE): current insights and therapeutic perspectives.

Brain & development
2025

Use of cannabidiol for off-label treatment of patients with refractory focal, genetic generalised and other epilepsies.

Neurological research and practice
2025

[Febrile infection-related epilepsy syndrome caused by hemophagocytic lymphohistiocytosis: a case report].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
2025

M4CEA: A Knowledge-guided Foundation Model for Childhood Epilepsy Analysis.

IEEE journal of biomedical and health informatics
2025

Current and Future Treatment Strategies in Developmental and/or Epileptic Encephalopathy With Spike-Wave Activation in Sleep (DEE-SWAS): A Time for Precision Medicine?

Pediatric neurology
2024

Clinical characteristics of 27 children with febrile infection-related epilepsy syndrome in a single center.

Pediatric discovery
2025

Clinical characteristics associated with photoparoxysmal response in routine electroencephalography.

Epileptic disorders : international epilepsy journal with videotape
2025

Retrospective multicenter study on cryptogenic NORSE/FIRES patients treated with anakinra.

Seizure
2025

Adult-Onset Febrile Infection-Related Epilepsy Syndrome Treated with Short-Term Anakinra.

Journal of epilepsy research
2025

Observational Study of Tocilizumab in Children With Febrile Infection-Related Epilepsy Syndrome.

Annals of clinical and translational neurology
2025

Expansion of the Epilepsy Genotype-Phenotype Spectrum: Genetic and Clinical Characterization of 288 Children with Epilepsy in China.

Seizure
2025

Focus on epilepsy and epilepsy syndromes in children with autism spectrum disorders: a study of 74 patients.

Brain & development
2025

DEPDC5-Related Familial Focal Epilepsy With Variable Foci-1: A Report of a Rare Case.

Cureus
2025

Amelogenesis Imperfecta and Epilepsy: A Diagnostic Clue to a Neurogenetic Epilepsy Syndrome.

Neurology
2025

Temporal Lobe Epilepsy Associated With Glutamic Acid Decarboxylase Antibodies: Defining a Distinct Epilepsy Syndrome.

Neurology(R) neuroimmunology & neuroinflammation
2025

PQBP1-dependent alternative RNA splicing underlies high calorie diet-induced cognitive impairment.

bioRxiv : the preprint server for biology
2025

Clinical and neuroimaging features of patients with claustrum sign.

Frontiers in neurology
2025

Minocycline in chronic management of febrile infection-related epilepsy syndrome (FIRES): a case series and literature review of treatment strategies.

Acta epileptologica
2025

SCN2A gene mutations with epilepsy: single center experience.

Italian journal of pediatrics
2025

Requirement Analysis for Data-Driven Electroencephalography Seizure Monitoring Software to Enhance Quality and Decision Making in Digital Care Pathways for Epilepsy: A Feasibility Study from the Perspectives of Health Care Professionals.

JMIR human factors
2025

An international survey on withdrawing the ketogenic diet therapy for epilepsy.

Epilepsy & behavior : E&B
2025

The changes in brain network functional gradients and dynamic functional connectivity in SeLECTS patients revealing disruptive and compensatory mechanisms in brain networks.

Frontiers in psychiatry
2025

Comparative clinical outcomes in children with Febrile Infection-Related Epilepsy Syndrome (FIRES).

Epilepsy & behavior : E&B
2025

Research progress on epilepsy with myoclonic absence.

Acta epileptologica
2025

Glymphatic system dysfunction and its impact on seizure severity, cognitive function, and affective symptoms in patients with generalized tonic-clonic seizures alone.

Journal of the neurological sciences
2025

Secondary sclerosing cholangitis in critically ill patients with febrile infection-related epilepsy syndrome (FIRES): a case series.

Frontiers in neurology
2025

Pediatric new-onset super-refractory status epilepticus (NOSRSE): a case-series.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
2025

Performance of cryptogenic new onset refractory status epilepticus score in a Brazilian cohort after testing for antineuronal antibodies with tissue-based and cell-based assays.

Epilepsia
2025

Appropriate selection of participants in pediatric developmental and epileptic encephalopathy trials: Lessons learned and future opportunities.

Epilepsia
2025

A Case Series and Review of Febrile-Infection Related Epilepsy Syndrome (FIRES).

Children (Basel, Switzerland)
2025

Intrathecal Dexamethasone as a FIRES Extinguisher: A 12-Patient Clinical Experience with Usage of Intrathecal Dexamethasone for Febrile Infection-Related Epilepsy Syndrome.

Neurocritical care
2025

Linking Memory Impairment to Structural Connectivity in Extrahippocampal Temporal Lobe Epilepsy Surgery.

Neurology international
2025

Comparative analysis of new-onset refractory status epilepticus in adult and pediatric patients: immunotherapy timing and functional outcomes.

Journal of neurology
2025

Adult-onset epilepsy with startle-induced seizure after febrile infection-related epilepsy syndrome: A case report.

Epileptic disorders : international epilepsy journal with videotape
2025

Potential inflammatory mechanisms of the ketogenic diet against febrile infection-related epilepsy syndrome.

Acta epileptologica
2024

SPOUT1 variants associated with autosomal-recessive developmental and epileptic encephalopathy.

Acta epileptologica
2025

Progressive Myoclonus Epilepsy: Distinctive MRI Changes in Cerebellar and Motor Networks.

Annals of clinical and translational neurology
2025

The phenotypic spectrum of YWHAG-related epilepsy: From mild febrile seizures to severe developmental delay and epileptic encephalopathy.

Developmental medicine and child neurology
2025

Clinical whole genome sequencing in pediatric epilepsy: Genetic and phenotypic spectrum of 733 individuals.

Epilepsia
2025

Gaze behavior in infancy associates with developmental outcome at the age of two years in early-onset epilepsies.

Epilepsy & behavior : E&B
2025

Diagnosing late-onset PKU in the shadow of refractory seizures.

Radiology case reports
2025

Epilepsy with myoclonic-atonic seizures: an update on genetic causes, nosological limits, and treatment strategies.

The Lancet. Neurology
2025

Epilepsy syndromes classification.

Epilepsia open
2025

Eye closure sensitivity and related EEG findings: Persistence rates and classification of epilepsy syndromes by the International League Against Epilepsy.

Epileptic disorders : international epilepsy journal with videotape
2025

Genetic Epilepsies With Onset in Infancy and Toddlerhood: A Prospective Single-Center Study in India.

Pediatric neurology
2026

Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication.

Epilepsy currents
2025

Clinical outcomes of cryptogenic new onset refractory status epilepticus (NORSE) in a tertiary hospital in Singapore: a case series.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

Treatment efficacy for infantile epileptic spasms syndrome in children with trisomy 21.

Frontiers in pediatrics
2025

Vagus nerve stimulation and fast parameter programming protocol in children with febrile infection-related epilepsy syndrome in ICU.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
2025

Febrile Infection-Related Epilepsy Syndrome (FIRES) in children: a retrospective cohort study.

European journal of pediatrics
2025

Potential Role of Perampanel in Reducing Barbiturate Dependency in Febrile Infection-Related Epilepsy Syndrome: A Case Report.

Cureus
2025

Innovative epilepsy management: a combined figure of EEG categorization and medication mechanisms.

Frontiers in neurology
2025

Combined Systemic Immunotherapy and Intrathecal Dexamethasone in Febrile Infection Related Epilepsy Syndrome.

Annals of clinical and translational neurology
2025

Challenges in Management of Febrile Infection-Related Epilepsy Syndrome: Real-World Experience From a Large Cohort of Pediatric Patients.

Pediatric neurology
2025

Early intrathecal dexamethasone (IT-Dexa) associated with faster recovery and good outcome in an adolescent with febrile infection-related epilepsy syndrome (FIRES).

BMJ case reports
2025

Classification and Diagnosis of Epilepsy.

Continuum (Minneapolis, Minn.)
2025

New-Onset Refractory Status Epilepticus and Febrile Infection-Related Epilepsy Syndrome Cases in Children: A Retrospective Cohort Study in South of Iran.

Iranian journal of child neurology
2025

Pulsatile Dexamethasone in Patients with Infantile Spasms: A Retrospective Analysis of a Unique Therapy Regime.

Neuropediatrics
2025

Brain changes in sleep-related hypermotor epilepsy observed from wakefulness and N2 sleep: A matched case-control study.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
2025

Association of Sleep Spindle Rate With Memory Consolidation in Children With Rolandic Epilepsy.

Neurology
2025

Age-associated differences in FIRES: Characterizing prodromal presentation and long-term outcomes via the web-based NORSE/FIRES Family Registry.

Epilepsia
2025

Incidence of childhood and youth epilepsy: A population-based prospective cohort study utilizing current International League Against Epilepsy classifications for seizures, syndromes, and etiologies.

Epilepsia
2024

Infantile Spasms in Pediatric Down Syndrome: Potential Mechanisms Driving Therapeutic Considerations.

Children (Basel, Switzerland)
2025

Navigating life after New-onset refractory status epilepticus (NORSE) and Febrile infection-related epilepsy syndrome (FIRES): Insights from caregiver and patient interviews.

Epilepsy & behavior : E&B
2025

Promising therapeutic strategies for Lennox-Gastaut syndrome: what's new?

Expert review of neurotherapeutics
2025

Favorable outcomes and FDG-PET changes following tocilizumab treatment for febrile infection-related epilepsy syndrome in a child.

International immunopharmacology
2024

A Multicenter Retrospective Observational Cohort Study of Seizure Freedom before Lennox-Gastaut Syndrome (the "Gap"). Opportunities for Prevention.

medRxiv : the preprint server for health sciences
2025

Evaluating the patient needs and tolerability of Clobazam liquid formulation (Likozam® 1 mg/mL): A French patient and care-givers' centered survey.

Epilepsy & behavior : E&B
2024

Improved effect of EEG-biofeedback intervention on cognitive function in childhood idiopathic epilepsy with ADHD: A retrospective study.

Heliyon
2025

Rapid seizure resolution with cannabidiol in medically refractory epilepsy with myoclonic-atonic seizures.

Epileptic disorders : international epilepsy journal with videotape
2024

[What is the assessment of the etiology of the epilepsy?].

La Revue du praticien
2024

Corrigendum: A practical approach to in-hospital management of new-onset refractory status epilepticus/febrile infection related epilepsy syndrome.

Frontiers in neurology
2025

Refractory and Super-Refractory Status Epilepticus: Therapeutic Options and Prognosis.

Neurologic clinics
2024

Identification of a novel ST3GAL5 variant in a Chinese boy with GM3 synthase deficiency and literature review of variants in the ST3GAL5 gene.

Orphanet journal of rare diseases
2025

Transition from pediatric to adult care system in patients with complex epilepsies: Necker model for transition evaluated on 70 consecutive patients.

Epilepsia
2025

Complex Febrile Seizures: Usual and the Unusual.

Indian journal of pediatrics
2024

Parvalbumin interneuron impairment causes synaptic transmission deficits and seizures in SCN8A developmental and epileptic encephalopathy.

JCI insight
2025

Progressive Myoclonus Epilepsy and Beyond: A Systematic Review of SEMA6B-related Disorders.

Neuropediatrics
2025

The clinical and genetic spectrum of paediatric speech and language disorders.

Brain : a journal of neurology
2024

Transorbital intraoperative electrocorticography-guided surgical resection for medically refractory developmental epileptic encephalopathy with spike-wave activation in sleep.

Epilepsy & behavior reports
2024

Hemiconvulsion-Hemiplegia-Epilepsy syndrome in a 3-year-old girl: A case report and literature review.

Radiology case reports
2024

Efficacy of add-on Cenobamate treatment in refractory epilepsy due to Rasmussen's encephalitis.

Epilepsia open
2025

First-Drug Efficacy and Drug-Resistant Epilepsy Rates in Children With New-Onset Epilepsies: A Multicenter Large Cohort Study.

Journal of child neurology
2024

Modeling Cortical Versus Hippocampal Network Dysfunction in a Human Brain Assembloid Model of Epilepsy and Intellectual Disability.

bioRxiv : the preprint server for biology
2024

Myelin oligodendrocyte glycoprotein antibody-associated cerebral cortical encephalitis with super-refractory status epilepticus.

Brain & development
2024

Repetitive Transcranial Magnetic Stimulation Modulates Brain Connectivity in Children with Self-limited Epilepsy with Centrotemporal Spikes.

medRxiv : the preprint server for health sciences
2024

Communication trends over time in new-onset refractory status epilepticus (NORSE): Interim analysis from the NORSE/FIRES Family Registry.

Epilepsy & behavior : E&B
2024

Developmental and epileptic encephalopathies.

Nature reviews. Disease primers
2024

Successful Management of Febrile Infection-Related Epilepsy Syndrome Using Cytokine-Directed Therapy.

Journal of child neurology
2024

Epigenetic insights into GABAergic development in Dravet Syndrome iPSC and therapeutic implications.

eLife
2025

Dravet-like syndrome with PCDH19 mutations in Taiwan - A multicenter study.

Pediatrics and neonatology
2024

Spectrum of Leukodystrophy and Genetic Leukoencephalopathy in Indian Population Diagnosed by Clinical Exome Sequencing and Clinical Utility.

Neurology. Genetics
2024

Electro-Clinical Features and Functional Connectivity Analysis in SYN1-Related Epilepsy.

Annals of neurology
2024

NORSE/FIRES: how can we advance our understanding of this devastating condition?

Frontiers in neurology
2024

Hemophagocytic lymphohistiocytosis in an adult patient with super-refractory status epilepticus.

Epilepsia open
2024

Predictors of drug-resistant epilepsy in childhood epilepsy syndromes: A subgroup analysis from a prospective cohort study.

Epilepsia
2025

International consensus definitions for infection-triggered encephalopathy syndromes.

Developmental medicine and child neurology
2024

GABRG2 mutations in genetic epilepsy with febrile seizures plus: structure, roles, and molecular genetics.

Journal of translational medicine
2024

The Efficacy of a Ketogenic Diet in a Case With Febrile Infection-Related Epilepsy Syndrome in the Chronic Phase: A Case Report.

Cureus
2024

Nocturnal paroxysmal dystonia to sleep-related hypermotor epilepsy: A critical review.

Epilepsia
2024

[Discontinuation of antiseizure medication in patients with epilepsy].

Der Nervenarzt
2024

Pathogenic genes implicated in sleep-related hypermotor epilepsy: a research progress update.

Frontiers in neurology
2024

Use of ketamine in Super Refractory Status Epilepticus: a systematic review.

Neurological research and practice
2024

Serial MRI Changes in Febrile Infection-Related Epilepsy Syndrome (FIRES): A Clinical and Radiologic Exploration.

Annals of Indian Academy of Neurology
2024

Identification of etiologies according to baseline clinical features of pediatric new-onset refractory status epilepticus in single center retrospective study.

Seizure
2024

Steroid-Responsive Involuntary Movements as a Remote Symptom of Febrile Infection-Related Epilepsy Syndrome.

Cureus
2024

Microstate-based brain network dynamics distinguishing temporal lobe epilepsy patients: A machine learning approach.

NeuroImage
2024

The 2017 and 2022 ILAE epilepsy classification systems identify needs and opportunities in care: A paediatric hospital-based study.

Epilepsy & behavior : E&B
2024

EEG in focal and generalized epilepsies: Pearls and perils.

Epilepsy & behavior : E&B
2024

Surgical treatment of epileptic encephalopathy with spike-and-wave activation in sleep: A systematic review and meta-analysis.

Seizure
2024

Autoimmune-associated seizure disorders.

Epileptic disorders : international epilepsy journal with videotape
2024

Sulthiame use in children with pharmacoresistant epilepsies: A retrospective study.

Epileptic disorders : international epilepsy journal with videotape
2024

Epilepsies with onset during the first year of life: A prospective study on syndromes, etiologies, and outcomes.

Epilepsia open
2024

Benign convulsions with mild gastroenteritis in children: An emerging acute symptomatic seizures.

Pediatric discovery
2024

Clinical research progress on intrathecal glucocorticoids in the treatment of infections: A review.

Medicine
2024

Updates from the International League Against Epilepsy Classification of Epilepsy (2017) and Focal Cortical Dysplasias (2022): Imaging Phenotype and Genetic Characterization.

AJNR. American journal of neuroradiology
2024

FADD gene pathogenic variants causing recurrent febrile infection-related epilepsy syndrome: Case report and literature review.

Epilepsia
2024

Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM.

Neurology
2024

Mosaicism-independent mechanisms contribute to Pcdh19-related epilepsy and repetitive behaviors in Xenopus.

Proceedings of the National Academy of Sciences of the United States of America
2024

Survey of Pediatric Status Epilepticus Treatment Practices and Adherence to Management Guidelines (Pedi-SPECTRUM e-Survey).

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine
2024

Dravet syndrome seizure frequency and clustering: Placebo-treated patients in clinical trials.

Epilepsy & behavior : E&B
2024

NORSE seasonality may vary geographically in adults.

Epilepsia open
2024

Improving epilepsy diagnosis across the lifespan: approaches and innovations.

The Lancet. Neurology
2024

Comparative analysis of patients with new onset refractory status epilepticus preceded by fever (febrile infection-related epilepsy syndrome) versus without prior fever: An interim analysis.

Epilepsia
2024

X-Linked Epilepsies: A Narrative Review.

International journal of molecular sciences
2024

Mice harboring the T316N variant in the GABAAR γ2 subunit exhibit sleep-related hypermotor epilepsy phenotypes and hypersynchronization in the thalamocortical pathway.

Experimental neurology
Ver todos os 337 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Síndrome epiléptico.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Síndrome epiléptico

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Patterns of Response to Treatment and Outcome of Childhood Absence Epilepsy: A Multicenter Study From Saudi Arabia.
    Pediatric neurology· 2026· PMID 41875828mais citado
  2. Investigation of adolescent cases diagnosed with idiopathic/genetic generalized epilepsy in terms of self-esteem, aggression, body perception, and alexithymia.
    European journal of pediatrics· 2026· PMID 41857384mais citado
  3. From clinical practice to mechanistic insights in ketogenic diets for epilepsy.
    The Lancet. Neurology· 2026· PMID 41831475mais citado
  4. [Febrile infection-related epilepsy syndrome (FIRES) with the claustrum sign in a 55-year-old woman: a case report].
    Rinsho shinkeigaku = Clinical neurology· 2026· PMID 41813187mais citado
  5. Epilepsy Phenotypic Spectrum of NUS1-Related Disorder: A Case Series.
    Annals of the Child Neurology Society· 2026· PMID 41716732mais citado
  6. Prospective Assessment of Cognitive Outcomes in Pediatric Self-Limited Epilepsy With Centrotemporal Spikes.
    Epilepsy Behav· 2026· PMID 41985205recente
  7. Intersection of Spinal Muscular Atrophy and Progressive Myoclonic Epilepsy Syndrome: ASAH1 Gene.
    Ann Indian Acad Neurol· 2026· PMID 41964139recente
  8. STRADA deficiency impairs cortical interneuron development in humans and mice.
    bioRxiv· 2026· PMID 41959176recente
  9. AFG2A-related encephalopathy, expanding the neurodevelopmental and epileptic spectrum.
    Orphanet J Rare Dis· 2026· PMID 41933351recente
  10. Topographical memory in transient epileptic amnesia.
    Epilepsy Behav· 2026· PMID 41926896recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:166463(Orphanet)
  2. MONDO:0015650(MONDO)
  3. Epilepsia(PCDT · Ministério da Saúde)
  4. GARD:20083(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q55785625(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Síndrome epiléptico
Compêndio · Raras BR

Síndrome epiléptico

ORPHA:166463 · MONDO:0015650
🇧🇷 Brasil SUS
Geral
Ensaios
9 ativos
Medicamentos
4 registrados
MedGen
UMLS
C0391958
Repurposing
14 candidatos
aminohydroxybutyric-acidcarbonic anhydrase inhibitor
diclofenamidesuccinimide antiepileptic
ethosuximideglutamate receptor antagonist
+11 outros
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades